Omnicare (OCR) 10-Q 23 Apr 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	3 Months Ended
	Mar. 31, 2014
Document Information [Line Items]	'
Entity Registrant Name	'OMNICARE INC
Entity Central Index Key	'0000353230
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Large Accelerated Filer
Document Type	'10-Q
Document Period End Date	31-Mar-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q1
Amendment Flag	'false
Entity Common Stock, Shares Outstanding	99,026,152

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME UNAUDITED (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Revenue, Net	$1,571,038	$1,458,945
Cost of sales	1,212,584	1,109,241
Gross profit	358,454	349,704
Selling, general and administrative expenses	186,813	190,693
Provision for doubtful accounts	21,561	24,010
Settlement, litigation and other related charges	7,052	22,619
Other charges	10,276	4,006
Operating income	132,752	108,376
Interest expense, net of investment income	-29,441	-29,462
Income before income taxes	103,311	78,914
Income tax (benefit) expense	39,673	30,600
Income from continuing operations	63,638	48,314
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	136	6,040
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	63,774	54,354
Income (Loss) from Continuing Operations, Per Basic Share	$0.65	$0.47
Earnings (loss) per common share - Basic:	'	'
Net income	$0.65	$0.53
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	$0	$0.06
Income (Loss) from Continuing Operations, Per Diluted Share	$0.59	$0.45
Earnings (loss) per common share - Diluted:	'	'
Diluted earnings per share (per share)	$0.59	$0.51
Dividends per common share	$0.20	$0.14
Weighted average number of common shares outstanding:	'	'
Weighted Average Number of Shares Outstanding, Basic	98,566	103,210
Diluted shares (in shares)	107,767	107,466
Comprehensive income (loss)	$63,997	$54,330

CONSOLIDATED_BALANCE_SHEETS_UN

CONSOLIDATED BALANCE SHEETS UNAUDITED (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$346,987	$356,001
Accounts receivable, less allowances of $209,140 (2012-$269,416)	755,620	695,684
Inventories	442,634	512,418
Deferred income tax benefits	126,738	135,094
Other current assets	277,113	265,536
Current assets of discontinued operations	46,659	49,995
Total current assets	1,995,751	2,014,728
Properties and equipment, at cost less accumulated depreciation of $342,659 (2012-$308,525)	317,856	305,888
Goodwill	4,057,456	4,057,456
Identifiable intangible assets, less accumulated amortization of $256,732 (2012-$236,116)	122,057	129,974
Other noncurrent assets	95,999	96,722
Non current assets of discontinued operations	85,059	87,078
Total noncurrent assets	4,678,427	4,677,118
Total assets	6,674,178	6,691,846
Current liabilities:	'	'
Accounts payable	231,639	181,022
Accrued employee compensation	45,593	50,240
Debt, Current	528,475	527,204
Other current liabilities	307,160	355,845
Current liabilities of discontinued operations	17,407	18,846
Total current liabilities	1,130,274	1,133,157
Current liabilities of continuing operations	584,392	587,107
Long-term debt, net	1,417,491	1,418,819
Deferred income tax liabilities	1,023,415	1,012,733
Other noncurrent liabilities	54,649	53,835
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	840	1,398
Total noncurrent liabilities	2,496,395	2,486,785
Total liabilities	3,626,669	3,619,942
Convertible Debt (Note 5)	329,425	331,101
Stockholders' equity:	'	'
Preferred stock, no par value, 1,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $1 par value, 200,000,000 shares authorized, 134,551,698 shares issued (2012-133,503,156 shares issued)	135,314	134,624
Paid in capital	2,117,652	2,047,195
Retained earnings	1,737,771	1,693,799
Treasury stock, at cost- 31,571,337 shares (2012-28,851,671 shares )	-1,270,335	-1,132,274
Accumulated Other Comprehensive Income (Loss), Net of Tax	-2,318	-2,541
Total stockholders' equity	2,718,084	2,740,803
Total liabilities and stockholders' equity	$6,674,178	$6,691,846

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Increase (decrease) in cash and cash equivalents of discontinued operations	$5,616	$1,717
Increase (decrease) in cash and cash equivalents of continuing operations	-9,014	53,888
Cash flows from operating activities:	'	'
Net income (loss)	63,774	54,354
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	-136	-6,040
Adjustments to reconcile net income to net cash flows from operating activities:	'	'
Depreciation expense	13,934	13,137
Amortization expense	19,802	18,852
Changes in assets and liabilities, net of effects from acquisition and divestiture of businesses:	'	'
Accounts receivable, net of provision for doubtful accounts	-64,041	17,640
Inventories	69,784	2,573
Other current and noncurrent assets	-4,450	-9,330
Accounts payable	54,154	-5,977
Accrued employee compensation	-4,647	-25,136
Current and noncurrent liabilities	23,412	46,391
Net cash flows from operating activities of continuing operations	171,586	106,464
Net cash flows from operating activities of discontinued operations	5,912	2,431
Net cash flows from operating activities	177,498	108,895
Cash flows from investing activities:	'	'
Disposition of business, net	3,629	0
Capital expenditures	-26,165	-22,415
Other	12	854
Net cash flows used in investing activities of continuing operations	-22,524	-21,561
Net cash flows used in investing activities of discontinued operations	-296	-714
Net cash flows used in investing activities	-22,820	-22,275
Cash flows from financing activities:	'	'
Payments on Term Loans	-5,313	-5,313
Payments on long-term borrowings and obligations	-39,030	-1,684
Increase (decrease) in cash overdraft balance	-3,537	-9,774
Payments for Omnicare common stock repurchases	-95,417	-302
Proceeds for stock awards and exercise of stock options, net of stock tendered in payment	3,968	445
Dividends paid	-19,596	-14,479
Other	849	92
Net Cash Provided by (Used in) Financing Activities	-158,076	-31,015
Net increase (decrease) in cash and cash equivalents	-3,398	55,605
Cash and cash equivalents at beginning of period	356,001	444,620
Cash and cash equivalents at end of period	$346,987	$498,508

CONSOLIDATED_BALANCE_SHEET_PAR

CONSOLIDATED BALANCE SHEET (PARENTHETICAL) (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Parenthetical Balance Sheet [Abstract]	'	'
Allowance for Doubtful Accounts Receivable, Current	$180,361	$202,602
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	268,209	263,603
Finite-Lived Intangible Assets, Accumulated Amortization	$235,486	$227,657
Preferred Stock, No Par Value	$0	$0
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$1	$1
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	135,313,998	134,623,736
Treasury Stock, Shares	36,287,846	34,013,923

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Omnicare, Inc. and its consolidated subsidiaries (“Omnicare” or the “Company”) have prepared the accompanying unaudited Consolidated Financial Statements in accordance with the accounting policies described in its consolidated financial statements and the notes thereto included in the Company's 2013 Annual Report on Form 10-K (“2013 Annual Report”), and the interim reporting requirements of Form 10-Q.  Accordingly, certain information and disclosures normally included in the annual financial statements have been condensed or omitted.  The Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and related notes included in the 2013 Annual Report and any related updates included in the Company’s periodic Securities and Exchange Commission (“SEC”) filings.  In 2013, the Company's end-of-life hospice pharmacy business ("Hospice") as well as certain retail operations ("Retail") qualified for discontinued operations treatment. The results from operations for all periods presented have been revised to reflect the results of these businesses as discontinued operations, including related expenses. See additional information at the "Discontinued Operations" note. Certain reclassifications of prior year amounts, primarily related to the reclassification for discontinued operations, have been made to conform to the current year presentation.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Interim Financial Data
	The interim financial data is unaudited; however, in the opinion of Omnicare management, all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the Omnicare consolidated results of operations, financial position and cash flows for the interim periods presented have been made.  All significant intercompany accounts and transactions have been eliminated.
	Stock-Based Compensation
	Stock-based compensation expense recognized in the Consolidated Statement of Comprehensive Income for stock options, restricted stock units, performance share units and stock awards totaled approximately $6 million and $5 million for the three months ended March 31, 2014 and 2013 respectively.
	Accounts Receivable
	The following table is an aging of the Company’s gross accounts receivable (net of allowances for contractual adjustments), aged based on payment terms and categorized based on the three primary types of accounts receivable characteristics (in thousands):
	March 31, 2014		Current and 0-180 Days Past Due				181 Days and Over Past Due			Total
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	234,075			$	49,819		$	283,894
	Facility payors		357,955				132,088			490,043
	Private Pay payors		78,768				83,276			162,044
	Total gross accounts receivable		$	670,798			$	265,183		$	935,981
	December 31, 2013
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	195,544			$	67,791		$	263,335
	Facility payors		328,444				146,751			475,195
	Private Pay payors		75,655				84,101			159,756
	Total gross accounts receivable		$	599,643			$	298,643		$	898,286
	Accumulated Other Comprehensive Income (Loss)
	Accumulated other comprehensive income (loss) ("AOCI") by component and in the aggregate, follows (in thousands):
			March 31,				December 31, 2013
			2014
	Unrealized loss on fair value of investments		$	(539	)		$	(702	)
	Pension and postemployment benefits		(1,779		)		(1,839		)
	Total accumulated other comprehensive income (loss), net		$	(2,318	)		$	(2,541	)
	The amounts are net of applicable tax benefits, which were not material at March 31, 2014 and December 31, 2013. The reclassifications out of AOCI did not materially affect any individual line item on the Consolidated Statement of Comprehensive Income.
	Fair Value
	The Company’s financial assets and liabilities, measured at fair value on a recurring basis, were as follows (in thousands):
							Based on
			Fair Value				Quoted Prices in Active Markets			Other Observable Inputs			Unobservable Inputs
							(Level 1)			(Level 2)			(Level 3)
	March 31, 2014
	Bond portfolio		$	25,167			$	—		$	25,167		$	—
	7.75% interest rate swap agreements - fair value hedge		19,766				—			19,766			—
	Derivatives		—				—			—			—
	Total		$	44,933			$	—		$	44,933		$	—
	December 31, 2013
	Bond portfolio		$	25,140			$	—		$	25,140		$	—
	7.75% interest rate swap agreements - fair value hedge		18,671				—			18,671			—
	Derivatives		—				—			—			—
	Total		$	43,811			$	—		$	43,811		$	—
	The fair value of the Company’s fixed-rate debt facilities are shown at the "Debt" note.
	Offsetting Assets and Liabilities
	The Company has interest rate swap agreements (the "Interest Rate Swap Agreements") with multiple counterparties on its 7.75% Senior Subordinated Notes due 2020 (the "2020 Notes"), which are subject to this guidance. The following table presents the Interest Rate Swap Agreements offsetting securities as of March 31, 2014 and December 31, 2013
										Gross Amounts not offset in the statement of financial position
	Interest Rate Swaps as of:	Gross amount of recognized assets (liabilities)			Gross amount offset in the statement of financial position			Net amount of assets (liabilities) presented in the statement of financial position		Financial instruments		Cash collateral received			Net amount
	31-Mar-14
	Swap A	$	10,013		$	—		$	10,013	$	—	$	—		$	10,013
	Swap B	9,753			—			9,753		—		—			9,753
		$	19,766		$	—		$	19,766	$	—	$	—		$	19,766
	December 31, 2013
	Swap A	$	9,408		$	—		$	9,408	$	—	$	—		$	9,408
	Swap B	9,263			—			9,263		—		—			9,263
		$	18,671		$	—		$	18,671	$	—	$	—		$	18,671
	Income Taxes
	The quarterly effective tax rates are different than the federal statutory rate largely as a result of the impact of state and local income taxes and certain non-deductible charges.
	Other Charges
	Other charges (on a pre-tax basis) consist of the following (in thousands):
		Three months ended
		March 31,
		2014				2013
	Separation and other costs	$	10,276			$	3,469
	Acquisition and other related costs	—				537
	Total - other charges	$	10,276			$	4,006
	Separation and Other Costs
In the three months ended March 31, 2014 and 2013, the Company recorded separation related costs and accelerated stock based compensation expense for certain employees of approximately $10 million and $3 million, respectively. These charges are reflected in the "Other charges" caption of the Consolidated Statement of Comprehensive Income and include charges related to the previously announced retirement of the Chief Executive Officer in the current quarter.
Restructuring and Other Related Charges
The Company continues to make payments in connection with its Company-wide Reorganization Program (the “CWR Program”), primarily related to certain severance amounts and its relocation of the corporate office. As of March 31, 2014, the Company has made cumulative payments of approximately $3 million for severance and other employee-related costs for the CWR Program.  The Company had liabilities related to the CWR Program of approximately $5 million at December 31, 2013, with utilization of approximately $1 million in the three months ended March 31, 2014. The remaining liabilities pursuant to the CWR Program of $4 million at March 31, 2014, represent amounts not yet paid relating to actions taken in connection with the CWR Program (primarily lease termination costs) and will be settled as these matters are finalized.
Common Stock Repurchase Program
In the three months ended March 31, 2014, the Company repurchased approximately 1.6 million shares through its authorized share repurchase program at an aggregate cost of approximately $95 million, for a cumulative amount of approximately 26 million shares of common stock repurchased at an aggregate cost of approximately $945 million from the inception of the share repurchase programs in May 2010 through March 31, 2014. In the three months ended March 31, 2013, the Company did not repurchase any shares through authorized share repurchase programs. The Company had approximately $405 million of share repurchase authority remaining as of March 31, 2014, which expires on December 31, 2015.
Capped Call
On April 2, 2012, the Company entered into capped call transactions with a counterparty, paying $48.1 million for the purchase of the capped calls, which were recorded as additional paid in capital. The capped call transactions are intended to reduce potential economic dilution upon conversion of the 3.75% Convertible Senior Subordinated Notes due 2042. The capped calls settle in tranches through March 2016, one of which settled in the first quarter of 2014. The adjusted strike price for the capped calls ranged from $40.96 to $41.05 and the adjusted cap price for the tranche settled in 2014 ranged from $56.75 to $56.88; the strike and cap prices adjust for the Company's dividend payments. The Company received approximately 0.6 million net shares upon settlement with a value of approximately $38 million.
Recently Issued Accounting Standards
There are no recently issued accounting standards that are expected to have a material impact on the Company's consolidated results of operations, financial position and cash flows.

Discontinued_operations_Notes

Discontinued operations (Notes)	3 Months Ended
	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	'
	In the fourth quarter of 2013, the Company's end-of-life hospice pharmacy business ("Hospice") as well as certain retail operations ("Retail") qualified for discontinued operations treatment. In the first quarter of 2014, the Company finalized the sale of several of the retail operations for net proceeds of approximately $3 million. The results from operations for all periods presented have been revised to reflect the results of Hospice and Retail as discontinued operations.
	Selected financial information related to the discontinued operations follows (in thousands):
		Three months ended March 31,
		2014			2013
	Net Sales
	Hospice	$	48,357		$	52,497
	Retail	10,170			13,561
	Net sales - total discontinued	58,527			66,058
	Income (loss) from operations, pretax
	Hospice	1,214			9,888
	Retail	(474		)	(114		)
	Income from operations - total discontinued, pretax	740			9,774
	Income tax (benefit) expense
	Hospice	776			3,783
	Retail	(172		)	(49		)
	Income tax expense - total discontinued	604			3,734
	Income (loss) from discontinued operations
	Hospice	438			6,105
	Retail	(302		)	(65		)
	Income (loss) from discontinued operations - total	$	136		$	6,040

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets [Text Block]	'
	There were no changes in the carrying amount of goodwill for the three months ended March 31, 2014.
	The Company’s intangible amortization expense for the three months ended March 31, 2014 and 2013 was approximately $8 million and $9 million, respectively.

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt [Abstract]	'
Debt Disclosure [Text Block]	'
	The following table summarizes the Company's debt (in thousands):
		March 31,			December 31,
		2014			2013
	Revolving loans, due 2017	$	—		$	—
	Senior term loan, due 2017	393,125			398,438
	7.75% senior subordinated notes, due 2020	400,000			400,000
	3.75% convertible senior subordinated notes, due 2025	132,375			132,408
	4.00% junior subordinated convertible debentures, due 2033	307,122			307,153
	3.25% convertible senior debentures, due 2035	427,500			427,500
	3.75% convertible senior subordinated notes, due 2042	390,000			390,000
	3.50% convertible senior subordinated notes, due 2044	424,250			424,250
	Capitalized lease and other debt obligations	18,755			20,685
	Subtotal	2,493,127			2,500,434
	Add interest rate swap agreements	19,766			18,671
	(Subtract) unamortized debt discount	(566,927		)	(573,082		)
	(Subtract) current portion of debt	(528,475		)	(527,204		)
	Total long-term debt, net	$	1,417,491		$	1,418,819
	3.75% Convertible Senior Subordinated Notes, due 2025
	Omnicare has outstanding approximately $132 million aggregate principal amount of 3.75% Convertible Senior Subordinated Notes due 2025 (the "2025 Notes"). The holders may convert their 2025 Notes, prior to December 15, 2023, on any date during any calendar quarter (and only during such calendar quarter) if the closing sale price of the Company's common stock was more than 130% of the then current conversion price for at least 20 trading days in the period of the 30 consecutive trading days ending on, and including, the last trading day of the previous quarter, or at any time on or after December 15, 2023 or under certain other specified circumstances. Upon conversion, the Company will pay cash and shares of its common stock, if any, based on a daily conversion value calculated on a proportionate basis for each day of the 25 trading-day cash settlement averaging period. The conversion price is $26.84 and the conversion threshold is $34.89 as of March 31, 2014. As of March 31, 2014 and December 31, 2013, the aforementioned conversion threshold had been attained. As a result, the 2025 Notes were convertible by the holders to cash and to common stock and have been classified as current debt, net of discount, on the Consolidated Balance Sheet as of March 31, 2014 and December 31, 2013.  Accordingly, since the terms of the 2025 Notes require the principal to be settled in cash, the Company reclassified from equity the portion of the 2025 Notes attributable to the conversion feature which had not yet been accreted to its face value.
	4.00% Junior Subordinated Convertible Debentures, due 2033
	Omnicare has outstanding $307 million aggregate principal amount of 4.00% Junior Subordinated convertible debentures, due 2033 (the “2033 Debentures”). The 2033 Debentures underlie the securities in the 4.00% Trust Preferred Income Equity Redeemable Securities ("Trust PIERS") of Omnicare Capital Trust I and Omnicare Capital Trust II (the "Series A Trust PIERS" and "Series B Trust PIERS", respectively). Each Trust PIERS represents an undivided beneficial interest in the assets of the applicable trust, which assets consist solely of a corresponding amount of 2033 Debentures. The Series A Trust PIERS and the Series B Trust PIERS have identical terms, except that the Series B Trust PIERS have a net share settlement feature. Holders may convert their Trust PIERS if the closing sale price of the Company's common stock was more than 130% of the then current conversion price for at least 20 trading days in the period of the 30 consecutive trading days ending on, and including, the last trading day of the previous quarter. The conversion price is $40.82 and the conversion threshold is $53.07 as of March 31, 2014. As of March 31, 2014 and December 31, 2013, the aforementioned conversion threshold had been attained. As a result, the Trust PIERS (and the underlying 2033 Debentures) were convertible by the holders and have been classified as current debt, net of discount, on the Consolidated Balance Sheet as of March 31, 2014 and December 31, 2013.  Accordingly, since the terms of the majority of the 2033 Debentures require the principal to be settled in cash, the Company reclassified from equity the portion attributable to the conversion feature which had not yet been accreted to its face value.
	In addition to the continued accrual of regular cash interest, contingent interest accrued on the Trust PIERS (and the underlying 2033 Debentures) for the period from December 15, 2013 to March 14, 2014 and will accrue for the period from March 15, 2014 to June 14, 2014 at a rate of 0.125% of the average trading price of the Trust PIERS for the five trading days ended December 12, 2013 and March 13, 2014, respectively. Contingent cash interest of approximately $0.09 per $50 stated liquidation amount of Trust PIERS (and per $50 principal amount of the underlying 2033 Debentures) was paid on March 17, 2014 and contingent cash interest of approximately $0.09 per $50 stated liquidation amount of Trust PIERS (and per $50 principal amount of the underlying 2033 Debentures) is expected to be paid on June 16, 2014.
	3.75% Convertible Senior Subordinated Notes, due 2042
	Omnicare has outstanding $390 million aggregate principal amount of 3.75% Convertible Senior Subordinated Notes due 2042 (the "2042 Notes").  The holders may convert their 2042 Notes, prior to April 1, 2040, on any date during any calendar quarter (and only during such calendar quarter) if the closing sale price of the Company's common stock was more than 130% of the then current conversion price for at least 20 trading days in the period of the 30 consecutive trading days ending on, and including, the last trading day of the previous quarter, or at any time on or after April 1, 2040 or under certain other specified circumstances. Upon conversion, the Company will pay cash and shares of its common stock, if any, based on a daily conversion value calculated on a proportionate basis for each day of the 25 trading-day cash settlement averaging period. The conversion price is $41.05 and the conversion threshold is $53.37 as of March 31, 2014. As of March 31, 2014 and December 31, 2013, the aforementioned conversion threshold had been attained. As a result, the 2042 Notes were convertible by the holders to cash and to common stock and have been classified as current debt, net of discount, on the Consolidated Balance Sheet as of March 31, 2014 and December 31, 2013. Accordingly, since the terms of the 2042 Notes require the principal to be settled in cash, the Company reclassified from equity the portion attributable to the conversion feature which had not yet been accreted to its face value.
	As outlined above, many of the Company’s outstanding notes and debentures are convertible into cash and/or shares of Omnicare common stock upon certain specified circumstances, including if the closing price of our common stock is more than 130% of the conversion price for such notes/debentures during the applicable measurement period (the "Convertible Notes"). In general, upon conversion, the Company will pay cash for the principal amount and shares of common stock for the remainder, if any, based on a daily conversion value during the applicable cash settlement averaging period; provided that the Company will pay cash in lieu of any fractional shares. Payment occurs at the end of the applicable settlement period, which is generally 30 days after the Company receives a holder’s notice of conversion. As of March 31, 2014, approximately $829 million in aggregate principal amount was convertible, which includes the 2025 Notes, the 2042 Notes and the 2033 Debentures.
	The amount convertible at any given time is subject to change depending on factors such as the price of the Company’s common stock during the applicable measurement period. The Company cannot predict the aggregate principal amount of Convertible Notes that will be convertible at any given time or how many, if any, holders of such Convertible Notes will present for conversion or the impact of any such conversions on results of operations, financial condition, liquidity or cash flows.
	As of March 31, 2014, there was $393 million outstanding under the Company's term loan.  The interest rate on the term loan was 1.91% at March 31, 2014. As of March 31, 2014, the Company had no outstanding balance under its revolving credit facility, except for approximately $14 million of standby letters of credit, substantially all of which are subject to automatic annual renewals.
	The weighted average floating interest rate on the Interest Rate Swap Agreements in the first quarter of 2014 was 4.20% versus the 7.75% stated rate on the corresponding 2020 Notes, which had a remaining principal balance of $400 million at March 31, 2014.
	The Company amortized to expense approximately $1 million of deferred debt issuance costs during each of the three month periods ended March 31, 2014 and 2013.
	Information relating to the Company's convertible securities at March 31, 2014 is in the following table:
	Convertible Debt	Carrying Value of Equity Component (in thousands)			Remaining Amortization Period		Effective Interest Rate
	3.75% convertible senior subordinated notes, due 2025	$	11,437		11.75		8.25	%
	4.00% junior subordinated convertible debentures, due 2033	$	118,348		19.25		8.01	%
	3.25% convertible senior debentures, due 2035	$	245,433		1.75		7.63	%
	3.75% convertible senior subordinated notes, due 2042	$	167,941		28		7.3	%
	3.50% convertible senior subordinated notes, due 2044	$	208,200		29.9		7.7	%
	The fair value of the Company’s fixed-rate debt facilities, excluding the Interest Rate Swap Agreements, is based on quoted market prices (Level II) and is summarized as follows (in thousands):
	Fair Value of Financial Instruments
		March 31, 2014							December 31, 2013
	Financial Instrument	Book Value			Market Value				Book Value		Market Value
	7.75% senior subordinated notes, due 2020	$	400,000		$	430,300			$	400,000	$	435,800
	3.75% convertible senior subordinated notes, due 2025
	Carrying value	87,848			—				87,310
	Unamortized debt discount	44,527			—				45,098
	Principal amount	132,375			299,200				132,408		306,500
	4.00% junior subordinated convertible debentures, due 2033
	Carrying value	186,773			—				186,136
	Unamortized debt discount	120,349			—				121,017
	Principal amount	307,122			450,300				307,153		455,900
	3.25% convertible senior debentures, due 2035
	Carrying value	397,146			—				393,126
	Unamortized debt discount	30,354			—				34,374
	Principal amount	427,500			454,800				427,500		457,400
	3.75% convertible senior subordinated notes, due 2042
	Carrying value	225,465			—				225,014
	Unamortized debt discount	164,535			—				164,986
	Principal amount	390,000			582,600				390,000		592,800
	3.50% convertible senior subordinated notes, due 2044
	Carrying value	217,088			—				216,643
	Unamortized debt discount	207,162			—				207,607
	Principal amount	424,250			432,600				424,250		428,500

Earnings_Loss_Per_Share_Data

Earnings (Loss) Per Share Data	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share Data	'
	The following is a reconciliation of the basic and diluted earnings per share (“EPS”) computations for both the numerator and denominator (in thousands, except per share data):
		Three months ended March 31,
	2014:00:00	Income (Numerator)		Common Shares(Denominator)	Per Common
					Share Amounts
	Basic EPS
	Income from continuing operations	$	63,638		$	0.65
	Income from discontinued operations	136			—
	Net income	$	63,774	98,566	$	0.65
	Effect of Dilutive Securities
	Convertible securities	66		8,463
	Stock options, units and awards	—		738
	Diluted EPS
	Income from continuing operations plus assumed conversions	$	63,704		$	0.59
	Income from discontinued operations	136			—
	Net income plus assumed conversions	$	63,840	107,767	$	0.59
		Three months ended March 31,
	2013:00:00	Income (Numerator)		Common Shares(Denominator)	Per Common
					Share Amounts
	Basic EPS
	Income from continuing operations	$	48,314		$	0.47
	Income from discontinued operations	6,040			0.06
	Net income	$	54,354	103,210	$	0.53
	Effect of Dilutive Securities
	Convertible securities	71		3,753
	Stock options, warrants, units and awards	—		503
	Diluted EPS
	Income from continuing operations plus assumed conversions	$	48,385		$	0.45
	Income from discontinued operations	6,040			0.06
	Net income plus assumed conversions	$	54,425	107,466	$	0.51
	EPS is reported independently for each amount presented.  Accordingly, the sum of the individual amounts may not necessarily equal the separately calculated amounts for the corresponding period.
	The Company is required to include additional shares in its diluted shares outstanding calculation based on the treasury stock method when the average market price of a share of Omnicare stock on the New York Stock Exchange for the applicable period exceeds the following amounts:
	Convertible Debt	Price
	3.75% convertible senior subordinated notes, due 2025	$	26.84
	4.00% junior subordinated convertible debentures, due 2033	$	40.82
	3.25% convertible senior debentures, due 2035	$	77.88
	3.75% convertible senior subordinated notes, due 2042	$	41.05
	3.50% convertible senior subordinated notes, due 2044	$	70
	Weighted average shares outstanding, assuming dilution, excludes the impact of immaterial amounts of stock options and stock awards for the three months ended March 31, 2014, and $2 million for the three months ended March 31, 2013, due to the exercise prices of these stock options and awards being greater than the average fair market value of our common stock during the period. Also, the Company has capped call provisions in place on our 3.75% convertible notes due 2042, which provide a hedge against economic dilution, but not against diluted share count under generally accepted accounting principles, up to an average stock price of approximately $68.75 through March 2016.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Omnicare continuously evaluates contingencies based upon the best available information.  The Company believes that liabilities have been recorded to the extent necessary in cases where the outcome is considered probable and reasonably estimable.  To the extent that resolution of contingencies results in amounts that vary from the Company's recorded liabilities, future earnings will be charged or credited accordingly.
	On March 21, 2014, a complaint entitled United States, et al., ex rel. Fox Rx, Inc. v. Dr. Reddy’s Inc., Omnicare, Inc., and NeighborCare, Inc., No. 13-CIV-3779 was served on Omnicare. The initial complaint was filed under seal on June 4, 2013 in the U.S. District Court for the Southern District of New York. The complaint was brought by Fox Rx., Inc. as a private party qui tam relator on behalf of the federal government and several states. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company entered into rebate arrangements with a manufacturer of generic simvastatin allegedly in violation of the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On December 4, 2013, a complaint entitled United States, et al., ex rel. Raymond Dolan v. Omnicare, Inc., et al. was served on Omnicare. The initial complaint, filed under seal on January 19, 2010 in the U.S. District Court for the Northern District of Illinois, was brought by Raymond Dolan as a private party qui tam relator on behalf of the federal government and the States of Illinois and North Carolina. The relator filed a First Amended Complaint on February 11, 2014. The relator asserts violations of the federal False Claims Act and analogous state laws based upon allegations that the Company entered into contracts with certain customer facilities in Illinois that included pricing for pharmaceuticals below Average Wholesale Price as well as other discounted pricing in return for referrals of business, allegedly in violation of the Stark Law, Medicare regulations, and the Anti-Kickback Statute. The U.S. Department of Justice notified the court on September 13, 2013 that it declined to intervene. On March 28, 2014, the Company filed a motion to dismiss the First Amended Complaint. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On November 26, 2013, a complaint entitled United States, et al., ex rel. Frank Kurnik v. Amgen, Inc., Omnicare, Inc., PharMerica Corp., and Kindred Healthcare, Inc., No. 3:11-cv-01464-JFA, was unsealed by the U.S. District Court for the District of South Carolina. The U.S. Department of Justice has notified the court that it intervened against Omnicare for the purposes of settlement. The complaint alleges violations of the False Claims Act stemming from activities in connection with agreements it had with the manufacturer of the pharmaceutical Aranesp that allegedly violated the Anti-Kickback Statute. In a previous filing, prior to the complaint being unsealed, the Company disclosed the underlying investigation by the U.S. Department of Justice, through the U.S. Attorney’s Office for the District of South Carolina. The Company previously recorded a provision related to this matter. On February 27, 2014, the Company agreed to a settlement of this matter in exchange for a payment of $4.2 million, which was accrued as of December 31, 2013. On February 28, 2014, the Court dismissed this case with prejudice.
	On November 18, 2013, a complaint entitled United States, et al., ex rel. Fox Rx, Inc. v. Omnicare, Inc., NeighborCare, Inc., PharMerica Corporation, and Managed Health Care Associates, Inc., No. 1:12-CIV-0275 was served on Omnicare. The initial complaint was filed under seal on January 12, 2012 in the U.S. District Court for the Southern District of New York. The complaint was brought by Fox Rx., Inc. as a private party qui tam relator on behalf of the federal government and several states. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company dispensed certain brand medications in lieu of generic alternatives in violation of state board of pharmacy regulations or state Medicaid laws, and allegations that the Company dispensed expired medications in violation of Medicare regulations. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On February 7, 2014, the relator filed a Second Amended Complaint. On February 28, 2014, the Company filed a motion to dismiss the Second Amended Complaint. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On July 29, 2013, a complaint entitled James D. “Buddy” Caldwell, Attorney General, ex rel. State of Louisiana v. Abbott Laboratories, Inc., et al., No. 603091, was served on Omnicare. The initial complaint was first filed against Abbott on June 30, 2011. Omnicare and other defendants were added on July 9, 2013. The complaint was brought by the Louisiana Attorney General alleging certain activities in connection with agreements Omnicare had with Abbott, the manufacturer of the pharmaceutical Depakote, violated the Louisiana Medical Assistance Program Integrity Laws and Unfair Trade Practices Act. On August 27, 2013, the Company removed this action to the United States District Court for the Middle District of Louisiana. On September 26, 2013, the State moved to remand the case to state court. The Company opposed the motion. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On May 23, 2013, a qui tam complaint entitled United States and the State of Illinois ex rel. Alan Litwiller v. Omnicare, Inc., No. 1:11-cv-08980, was unsealed by the U.S. District Court for the Northern District of Illinois, Eastern Division. The complaint was brought by Alan Litwiller as a private party qui tam relator on behalf of the federal government and the State of Illinois. The action alleges civil violations of the federal False Claims Act and analogous Illinois state law based upon allegations that the Company agreed to forego collection of certain debts, provided certain credits or refunds to customers, provided charitable donations to charities associated with certain customers, and provided other services below cost for referrals of business in violation of the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On September 16, 2013, the Company filed a motion to dismiss the relator’s claims. On April 14, 2014, the court granted in part and denied in part the Company's motion to dismiss. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On March 22, 2013, a qui tam complaint entitled United States et al. ex rel. Susan Ruscher v. Omnicare, Inc. et al., Civil No. 08-cv-3396, which had been filed under seal in the U.S. District Court for the Southern District of Texas, was unsealed by the court. The complaint was brought by Susan Ruscher as a private party qui tam relator on behalf of the federal government and several state governments. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company’s practices relating to customer collections violated the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action at this time. On September 6, 2013, the relator filed a Third Amended Complaint. On November 5, 2013, the Company filed a motion to dismiss the Third Amended Complaint. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On March 11, 2013, a qui tam complaint entitled United States et al. ex rel. Marc Silver v. Omnicare, Inc. et al. Civil No. 1:11-cv-01326, which had been filed under seal in the U.S. District Court for the District of New Jersey, was unsealed by the court. The complaint was brought by Marc Silver as a private party qui tam relator on behalf of the federal government and several state governments. The action alleges civil violations of the federal False Claims Act and analogous state laws based upon allegations that the Company provided certain customer facilities with discounts and other forms of remuneration in return for referrals of business in violation of the Anti-Kickback Statute. The U.S. Department of Justice has notified the court that it declined to intervene in this action. On August 30, 2013, the Company filed a motion to dismiss the complaint. On October 22, 2013, as part of the agreement in principle to settle the claims alleged in the Gale complaint (as described below), the Company agreed with the relator to settle certain federal claims alleged in the Silver complaint. The agreement in principle was not effectuated. On November 12, 2013, the relator filed his Third Amended Complaint and on December 6, 2013, the Company filed a Motion to Dismiss the Third Amended Complaint. On January 24, 2014, as part of the revised agreement in principle to settle the claims alleged in the Gale complaint, the Company agreed to pay $8.24 million and no attorneys’ fees to settle all state claims in the Silver complaint and the U.S. Department of Justice agreed to have all federal claims in the Silver complaint dismissed with prejudice. This agreement in principle is subject to approval by the federal and state governments and execution of definitive settlement documentation. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be executed or as to the final terms of such settlement.
	On October 5, 2011, a qui tam complaint, entitled United States ex rel. Donald Gale v. Omnicare, Inc., No. 1:10-cv-0127, was served on the Company. The case had been filed on January 19, 2010 under seal with the U.S. District Court for the Northern District of Ohio, Eastern Division. The complaint was unsealed by the court on June 9, 2011 after the U.S. Department of Justice notified the court that it has declined to intervene in this action. The complaint was brought by Donald Gale as a private party qui tam relator on behalf of the federal government. The action alleges civil violations of the False Claims Act based on allegations that the Company provided certain customer facilities with discounts and other forms of remuneration in return for referrals of business in violation of the Anti-Kickback Statute, and offered pricing terms in violation of the “most favored customer” pricing laws of various state Medicaid plans. The Company filed a motion to dismiss on January 27, 2012. On September 26, 2012, the court granted in part and denied in part the Company’s motion to dismiss. On October 22, 2013, the Company reached an agreement in principle, without admitting liability, with the relator, pursuant to which the Company agreed to pay $120 million, plus attorneys’ fees, to settle the relator’s alleged claims, as well as certain claims alleged in the Silver complaint (described above). On December 6, 2013, after approval by the U.S. Department of Justice, the Company and the relator executed settlement documentation. Prior to the case being dismissed, the court learned of a potential breach of the seal by the relator and potential misrepresentations by the relator and his attorneys and held a hearing on January 9, 2014 to reconsider the court’s prior order denying the Company’s motion for disqualification of the relator and dismissal of the action and the Company's additional motion for sanctions. Prior to the court’s decision on the reconsideration motion and a motion for sanctions against the relator and his attorneys, on January 24, 2014, the Company reached an agreement in principle, without admitting liability, with the U.S. Department of Justice (which was granted leave to intervene on February 20, 2014), in which the Company agreed to pay $116 million and no attorneys’ fees to settle the claims alleged in the Gale complaint and to pay $8.24 million and no attorneys’ fees to settle all the state claims alleged in the Silver complaint and the U.S. Department of Justice agreed to have federal claims alleged in the Silver complaint dismissed with prejudice. In addition, the Company and the relator reached an agreement in principle pursuant to which the relator will pay the Company $4.24 million to settle the motion for sanctions. These agreements in principle are subject to approval by the federal and state governments and execution of definitive settlement documentation. The Company recorded a provision equal to the net settlement amount and an estimate of legal fees in its financial results for the year ended December 31, 2013. While the Company believes that a final settlement will be reached, there can be no assurance that any final settlement agreement will be executed or as to the final terms of such settlement.
	On August 4, 2011, a qui tam complaint, entitled United States ex rel. Fox Rx, Inc. v. Omnicare, Inc. and Neighborcare, Inc., No. 1:11-cv-0962, which was filed under seal with the U.S. District Court for the Northern District of Georgia, was unsealed by the court. The U.S. Department of Justice declined to intervene in this action. The Company was served with the complaint on November 23, 2011. The complaint was brought by Fox Rx, Inc. as a private party qui tam relator on behalf of the federal government. The action alleges civil violations of the False Claims Act based on allegations that the Company billed Medicare Part D for medically unnecessary antipsychotic drugs, increased the dispensing fees by artificially shortening the supply of prescribed medication, submitted claims for antipsychotic drugs without complying with Fox Rx, Inc.’s prior approval requirements, and waived or failed to collect copayments from patients to induce the use of prescription drugs. The Company filed a motion to dismiss on December 21, 2011. On August 29, 2012, the court granted the Company’s motion to dismiss, though granting leave to replead certain counts. On September 18, 2012, the relator filed a Third Amended Complaint reasserting its claims regarding copayments and antipsychotic drugs. On October 2 and 5, 2012, the Company filed motions to dismiss the Third Amended Complaint. On May 17, 2013, the court granted in part and denied in part the Company’s motions to dismiss. The court dismissed all claims except those related to prescriptions filled for Fox patients between 2009 and 2010. On December 2, 2013, the Company filed a motion for summary judgment on all remaining claims in the case. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On August 24, 2011, a class action complaint entitled Ansfield v. Omnicare, Inc., et al. was filed on behalf of a putative class of all purchasers of the Company’s common stock from January 10, 2007 through August 5, 2010 against the Company and certain of its current and former officers in the U.S. District Court for the Eastern District of Kentucky, alleging violations of federal securities laws in connection with alleged false and misleading statements with respect to the Company’s compliance with federal and state Medicare and Medicaid laws and regulations. On October 21, 2011, a class action complaint entitled Jacksonville Police & Fire Pension Fund v. Omnicare, Inc. et al. was filed on behalf of the same putative class of purchasers as is referenced in the Ansfield complaint, against the Company and certain of its current and former officers, in the U.S. District Court for the Eastern District of Kentucky. Plaintiffs allege substantially the same violations of federal securities law as are alleged in the Ansfield complaint. Both complaints seek unspecified money damages. The court has appointed lead counsel and a consolidated amended complaint was filed on May 11, 2012. The Company filed a motion to dismiss on July 16, 2012. On March 27, 2013, the court granted the Company’s motion to dismiss and dismissed all claims with prejudice. On April 26, 2013, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Sixth Circuit appealing the District Court’s order dismissing the complaint with prejudice. The parties completed oral argument before the Sixth Circuit on January 30, 2014. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	On October 29, 2010, a qui tam complaint entitled United States et al., ex rel. Banigan and Templin v. Organon USA, Inc., Omnicare, Inc. and PharMerica Corporation, Civil No. 07-12153-RWZ, that had been filed under seal with the U.S. District Court in Boston, Massachusetts, was ordered unsealed by the court. The complaint was brought by James Banigan and Richard Templin, former employees of Organon, as private party qui tam relators on behalf of the federal government and several state and local governments. The action alleges civil violations of the False Claims Act based on allegations that Organon USA, Inc. and its affiliates paid the Company and several other long-term care pharmacies rebates, post-purchase discounts and other forms of remuneration in return for purchasing pharmaceuticals from Organon and taking steps to increase the purchase of Organon’s drugs in violation of the Anti-Kickback Statute. The U.S. Department of Justice declined to intervene in this action. The court denied the Company’s motion to dismiss on June 1, 2012. Discovery is ongoing in this matter. The Company believes that the allegations are without merit and intends to vigorously defend itself in this action.
	The U.S. Department of Justice, through the U.S. Attorney’s Office for the Western District of Virginia, is investigating whether the Company’s activities in connection with agreements it had with the manufacturer of the pharmaceutical Depakote violated the False Claims Act or the Anti-Kickback Statute. The Company is cooperating with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter.
	The U.S. Department of Justice is investigating whether certain of the Company's practices relating to customer collections violated the False Claims Act or the Anti-Kickback Statute.  The Company is cooperating with this investigation and believes that it has complied with applicable laws and regulations with respect to this matter.
	On November 19, 2010, the Company was served with a second amended qui tam complaint entitled United States ex rel. Rostholder v. Omnicare, Inc. and Omnicare Distribution Center, LLC f/k/a Heartland Repack Services LLC, No. CCB-07-1283, which was filed under seal with the U.S. District Court in Baltimore, Maryland in May 2007. The U.S. Department of Justice notified the court on April 22, 2009 that it declined to intervene in this action. The complaint was brought by Barry Rostholder as a private party qui tam relator on behalf of the federal government and several state and local governments. The action, in general, alleges civil violations of the False Claims Act based on allegations that the Company submitted claims for reimbursement for drugs that were repackaged at its Heartland repackaging facility in violation of certain FDA regulations. These allegations arise from the previously disclosed issues experienced by the Company at its Heartland repackaging facility, which suspended operations in 2006. On September 30, 2011, the Company filed a motion to dismiss the lawsuit in its entirety. On August 14, 2012, the court granted the Company’s motion with prejudice as to the relator and without prejudice as to the United States. The relator filed an amended motion for reconsideration on September 10, 2012. On October 19, 2012, the court denied the relator’s motion to reconsider. On November 16, 2012, the relator filed a Notice of Appeal to the U.S. Court of Appeals for the Fourth Circuit from the District Court’s denial of the motion to reconsider and granting of the Company’s motion to dismiss. On February 21, 2014, the U.S. Court of Appeals for the Fourth Circuit upheld the United States District Court’s dismissal of the lawsuit with prejudice.
	As part of the previously disclosed civil settlement agreement entered into by the Company with the U.S. Attorney’s Office, District of Massachusetts in November 2009, the Company also entered into an amended and restated corporate integrity agreement (“CIA”) with the Department of Health and Human Services Office of the Inspector General (“OIG”) with a term of five years from November 2, 2009. Pursuant to the CIA, the Company is required, among other things, to (i) create procedures designed to ensure that each existing, new or renewed arrangement with any actual or potential source of health care business or referrals to Omnicare or any actual or potential recipient of health care business or referrals from Omnicare does not violate the Anti-Kickback Statute, 42 U.S.C. (§) 1320a-7b(b) or related regulations, directives and guidance, including creating and maintaining a database of such arrangements; (ii) retain an independent review organization to review the Company’s compliance with the terms of the CIA and report to OIG regarding that compliance; and (iii) provide training for certain Company employees as to the Company’s requirements under the CIA. The requirements of the Company’s prior corporate integrity agreement obligating the Company to create and maintain procedures designed to ensure that all therapeutic interchange programs are developed and implemented by Omnicare consistent with the CIA and federal and state laws for obtaining prior authorization from the prescriber before making a therapeutic interchange of a drug and to maintain procedures for the accurate preparation and submission of claims for federal health care program beneficiaries in hospice programs, have been incorporated into the amended and restated CIA without modification. The requirements of the CIA have resulted in increased costs to maintain the Company’s compliance program and greater scrutiny by federal regulatory authorities. Violations of the CIA could subject the Company to significant monetary penalties. Consistent with the CIA, the Company is reviewing its contracts to ensure compliance with applicable laws and regulations. As a result of this review, pricing under certain of its consultant pharmacist services contracts has increased and will continue to increase.
	In February 2006, two substantially similar putative class action lawsuits were filed in the U.S. District Court for the Eastern District of Kentucky, and were consolidated and entitled Indiana State Dist. Council of Laborers & HOD Carriers Pension & Welfare Fund v. Omnicare, Inc., et al., No. 2:06cv26. The amended consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought their shares in the Company’s public offering in December 2005. The complaint contained claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (and Rule 10b-5) and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. Plaintiffs alleged that Omnicare (i) artificially inflated its earnings (and failed to file GAAP-compliant financial statements) by engaging in improper generic drug substitution, improper revenue recognition and overvaluation of receivables and inventories; (ii) failed to timely disclose its contractual dispute with UnitedHealth Group Inc.; (iii) failed to timely record certain special litigation reserves; and (iv) made other allegedly false and misleading statements about the Company’s business, prospects, and compliance with applicable laws and regulations. The defendants filed a motion to dismiss the amended complaint on March 12, 2007, and on October 12, 2007, the district court dismissed the case. On November 9, 2007, plaintiffs appealed the dismissal to the U.S. Court of Appeals for the Sixth Circuit. On October 21, 2009, the Sixth Circuit Court of Appeals generally affirmed the district court’s dismissal, dismissing plaintiff’s claims for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. However, the appellate court reversed the dismissal for the claim brought for violation of Section 11 of the Securities Act of 1933, and returned the case to the district court for further proceedings. On July 14, 2011, the district court granted plaintiffs’ motion to file a third amended complaint. This complaint asserts a claim under Section 11 of the Securities Act of 1933 on behalf of all purchasers of Omnicare common stock in the December 2005 public offering. The new complaint alleges that the 2005 registration statement contained false and misleading statements regarding Omnicare’s policy of compliance with all applicable laws and regulations with particular emphasis on allegations of violation of the federal Anti-Kickback Statute in connection with three of Omnicare’s acquisitions, Omnicare’s contracts with two of its suppliers, and its provision of pharmacist consultant services. On August 19, 2011, the defendants filed a motion to dismiss the plaintiffs’ most recent complaint and on February 13, 2012 the district court dismissed the case and struck the case from the docket. On March 12, 2012, the plaintiffs filed a notice of appeal in the U.S. Court of Appeals for the Sixth Circuit. On May 23, 2013, the U.S. Court of Appeals affirmed in part and reversed and remanded in part the dismissal of the plaintiffs’ complaint. On June 6, 2013, the Company petitioned the Court of Appeals for a rehearing en banc. The petition for rehearing en banc was denied on July 23, 2013. On October 4, 2013 the Company filed a petition for writ of certiorari in the United States Supreme Court. On March 3, 2014, the United States Supreme Court granted the Company’s petition for writ of certiorari.
	The three months ended March 31, 2014 and 2013 included charges of $7.1 million and approximately $22.6 million, respectively, reflected in “Settlement, litigation and other related charges” on the Consolidated Statement of Comprehensive Income, primarily for estimated litigation and other related settlements and associated professional expenses for resolution of certain large customer disputes, certain regulatory matters with the federal government and various states, qui tam lawsuits, and costs associated with the purported class and derivative actions against the Company.  In connection with Omnicare's participation in Medicare, Medicaid, and other healthcare programs, the Company is subject to various inspections, audits, inquiries, and investigations by governmental/regulatory authorities responsible for enforcing the laws and regulations to which the Company is subject.  Further, the Company maintains a compliance program which establishes certain routine periodic monitoring of the accuracy of the Company's billing systems and other regulatory compliance matters and encourages the reporting of errors and inaccuracies.  As a result of the compliance program, Omnicare has made, and will continue to make, disclosures to the applicable governmental agencies of amounts, if any, determined to represent over-payments from the respective programs and, where applicable, those amounts, as well as any amounts relating to certain inspections, audits, inquiries, and investigations activity are included in “Settlement, litigation and other related charges” on the Consolidated Statement of Comprehensive Income.
	Although the Company cannot know the ultimate outcome of the matters described in the preceding paragraphs other than as disclosed, there can be no assurance that the resolution of these matters will not have a material adverse impact on the Company’s consolidated results of operations, financial position or cash flows or, in the case of other billing matters, that these matters will be resolved in an amount that would not exceed the amount of the pretax charges previously recorded by the Company.
	As part of its ongoing operations, the Company is subject to various inspections, audits, inquiries, investigations, and similar actions by third parties, as well as governmental/regulatory authorities responsible for enforcing the laws and regulations to which the Company is subject. Further, under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. In addition to the inquiries discussed above, the Company from time to time receives government inquiries from federal and state agencies regarding compliance with various healthcare laws. The Company is also involved in various legal actions arising in the normal course of business. At any point in time, the Company is in varying stages of discussions on these matters. Omnicare records accruals for such contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These matters are continuously being evaluated and, in many cases, are being contested by the Company and the outcome is not predictable.
	The inherently unpredictable nature of legal proceedings may be exacerbated by various factors from time to time, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes. With respect to violations of the False Claims Act, treble damages and/or additional penalties per claim will apply. Consequently, unless otherwise stated, no estimate of the possible loss or range of loss in excess of the amounts accrued, if any, can be made at this time regarding the matters described above. Further, there can be no assurance that the ultimate resolution of these matters, individually or in the aggregate, will not have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows.
	The Company indemnifies its directors and officers for certain liabilities that might arise from the performance of their job responsibilities for the Company.  Additionally, in the normal course of business, the Company enters into contracts that contain a variety of representations and warranties and which provide general indemnifications.  The Company’s maximum exposure under these arrangements is unknown, as this involves the resolution of claims made, or future claims that may be made, against the Company, its directors and/or officers, the outcomes of which are unknown and not currently predictable.  Accordingly, no liabilities have been recorded for the indemnifications.

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	The Company is organized in two operating segments, Long-Term Care Group ("LTC") and Specialty Care Group ("SCG"). These segments are based on the operations of the underlying businesses and the customers they serve. The Company's larger reportable segment is LTC, which primarily provides distribution of pharmaceuticals, related pharmacy consulting and other ancillary services. LTC's customers are primarily skilled nursing, assisted living and other providers of healthcare services. The Company’s other reportable segment is SCG, which provides specialty pharmacy and key commercialization services for the biopharmaceutical industry. The primary components of the "Corporate/Other" segment are the Company's corporate management oversight and administration, including its information technology and data management services, as well as other consolidating and eliminating entries, which have not been charged to reportable segments. The Company evaluates the performance of its segments based on revenue and operating income, and does not include segment assets or nonoperating income/expense items for management reporting purposes.
		For the three months ended March 31,
	2014:00:00	LTC			SCG			Corporate/Other			Consolidated
											Totals
	Net sales	$	1,191,253		$	379,672		$	113		$	1,571,038
	Depreciation and amortization expense	(17,471		)	(1,127		)	(15,138		)	(33,736		)
	Settlement, litigation and other related charges	(7,052		)	—			—			(7,052		)
	Other charges	(2,511		)	—			(7,765		)	(10,276		)
	Operating income (loss)	152,584			31,729			(51,561		)	132,752
	2013:00:00
	Net sales	$	1,141,585		$	316,729		$	631		$	1,458,945
	Depreciation and amortization expense	(18,030		)	(1,103		)	(12,856		)	(31,989		)
	Settlement, litigation and other related charges	(22,619		)	—			—			(22,619		)
	Other charges	(2,752		)	—			(1,254		)	(4,006		)
	Operating income (loss)	129,817			28,109			(49,550		)	108,376

Guarantor_Subsidiaries

Guarantor Subsidiaries	3 Months Ended
	Mar. 31, 2014
Guarantor Subsidiaries [Abstract]	'
Schedules Of Condensed Financial Statements [Text Block]	'
	The 2020 Notes, the 2025 Notes, the 2042 Notes, and the 3.50% Convertible Senior Subordinated Notes, due 2044 are fully and unconditionally guaranteed, subject to certain customary release provisions, on an unsecured, joint and several basis by certain wholly-owned subsidiaries of the Company (the “Guarantor Subsidiaries”).  The following condensed consolidating unaudited financial data illustrates the composition of Omnicare, Inc. (“Parent”), the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries as of March 31, 2014 and December 31, 2013 for the balance sheets, as well as the three months ended March 31, 2014 and 2013 for the statements of comprehensive income (loss) and the statements of cash flows.  Management believes separate complete financial statements of the Guarantor Subsidiaries would not provide information that would be necessary for evaluating the sufficiency of the Guarantor Subsidiaries, and thus are not presented.  The equity method has been used with respect to the Parent company’s investment in subsidiaries.  No consolidating/eliminating adjustment column is presented for the condensed consolidating statements of cash flows since there were no significant consolidating/eliminating adjustment amounts during the periods presented.
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the three months ended March 31,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	1,540,006		$	31,032		$	—		$	1,571,038
	Cost of sales	—			1,194,399			18,185			—			1,212,584
	Gross profit	—			345,607			12,847			—			358,454
	Selling, general and administrative expenses	987			182,120			3,706			—			186,813
	Provision for doubtful accounts	—			21,047			514			—			21,561
	Settlement, litigation and other related charges	—			7,052			—			—			7,052
	Other charges	—			10,276			—			—			10,276
	Operating income (loss)	(987		)	125,112			8,627			—			132,752
	Interest expense, net of investment income	(29,156		)	(285		)	—			—			(29,441		)
	Income (loss) before income taxes	(30,143		)	124,827			8,627			—			103,311
	Income tax (benefit) expense	(11,671		)	48,004			3,340			—			39,673
	Income (loss) from continuing operations	(18,472		)	76,823			5,287			—			63,638
	Income (loss) from discontinued operations	—			171			(35		)	—			136
	Equity of net income of subsidiaries	82,246			—			—			(82,246		)	—
	Net income	$	63,774		$	76,994		$	5,252		$	(82,246	)	$	63,774
	Comprehensive income	$	63,997		$	76,994		$	5,252		$	(82,246	)	$	63,997
	2013:00:00
	Net sales	$	—		$	1,427,130		$	31,815		$	—		$	1,458,945
	Cost of sales	—			1,091,162			18,079			—			1,109,241
	Gross profit	—			335,968			13,736			—			349,704
	Selling, general and administrative expenses	1,006			184,978			4,709			—			190,693
	Provision for doubtful accounts	—			23,532			478			—			24,010
	Settlement, litigation and other related charges	—			22,619			—			—			22,619
	Other charges	—			4,006			—			—			4,006
	Operating income (loss)	(1,006		)	100,833			8,549			—			108,376
	Interest expense, net of investment income	(28,991		)	(293		)	(178		)	—			(29,462		)
	Income (loss) before income taxes	(29,997		)	100,540			8,371			—			78,914
	Income tax (benefit) expense	(11,546		)	38,924			3,222			—			30,600
	Income (loss) from continuing operations	(18,451		)	61,616			5,149			—			48,314
	Income (loss) from discontinued operations	—			6,063			(23		)	—			6,040
	Equity of net income of subsidiaries	72,805			—			—			(72,805		)	—
	Net income	$	54,354		$	67,679		$	5,126		$	(72,805	)	$	54,354
	Comprehensive income	$	54,330		$	67,679		$	5,126		$	(72,805	)	$	54,330
	Note 10 - Guarantor Subsidiaries (Continued)
	Condensed Consolidating Balance Sheets
	(in thousands)
	As of March 31, 2014:	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
	ASSETS
	Cash and cash equivalents	$	284,410		$	49,777		$	12,800		$	—		$	346,987
	Accounts receivable, net (including intercompany)	—			752,924			336,511			(333,815		)	755,620
	Inventories	—			435,847			6,787			—			442,634
	Deferred income tax benefits, net-current	—			126,717			21			—			126,738
	Other current assets	1,407			250,744			24,962			—			277,113
	Current assets of discontinued operations	—			46,537			122			—			46,659
	Total current assets	285,817			1,662,546			381,203			(333,815		)	1,995,751
	Properties and equipment, net	—			313,016			4,840			—			317,856
	Goodwill	—			4,028,651			28,805			—			4,057,456
	Identifiable intangible assets, net	—			120,093			1,964			—			122,057
	Other noncurrent assets	42,079			53,855			65			—			95,999
	Noncurrent assets of discontinued operations	—			85,028			31			—			85,059
	Investment in subsidiaries	5,059,898			—			—			(5,059,898		)	—
	Total assets	$	5,387,794		$	6,263,189		$	416,908		$	(5,393,713	)	$	6,674,178
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities (including intercompany)	$	37,402		$	852,060		$	28,745		$	(333,815	)	$	584,392
	Current portion of long term debt	528,475			—			—			—			528,475
	Current liabilities of discontinued operations	—			17,404			3			—			17,407
Long-term debt, notes and convertible debentures	1,405,876			11,615			—			—			1,417,491
Deferred income tax liabilities	368,532			640,955			13,928			—			1,023,415
Other noncurrent liabilities	—			52,960			1,689			—			54,649
Noncurrent liabilities of discontinued operations	—			840			—			—			840
Convertible debt	329,425			—			—			—			329,425
Stockholders' equity	2,718,084			4,687,355			372,543			(5,059,898		)	2,718,084
Total liabilities and stockholders' equity	$	5,387,794		$	6,263,189		$	416,908		$	(5,393,713	)	$	6,674,178
As of December 31, 2013:
ASSETS
Cash and cash equivalents	$	275,910		$	68,050		$	12,041		$	—		$	356,001
Accounts receivable, net (including intercompany)	—			693,729			315,323			(313,368		)	695,684
Inventories	—			505,567			6,851			—			512,418
Deferred income tax benefits, net-current	—			135,148			—			(54		)	135,094
Other current assets	1,989			242,166			21,381			—			265,536
Current assets of discontinued operations	—			49,128			867			—			49,995
Total current assets	277,899			1,693,788			356,463			(313,422		)	2,014,728
Properties and equipment, net	—			301,200			4,688			—			305,888
Goodwill	—			4,028,651			28,805			—			4,057,456
Identifiable intangible assets, net	—			127,798			2,176			—			129,974
Other noncurrent assets	41,825			54,834			63			—			96,722
Noncurrent assets of discontinued operations	—			87,047			31			—			87,078
Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
Total assets	$	5,451,004		$	6,293,318		$	392,226		$	(5,444,702	)	$	6,691,846
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities (including intercompany)	$	83,028		$	793,461		$	23,986		$	(313,368	)	$	587,107
Current portion of long term debt	527,204			—			—			—			527,204
Current liabilities of discontinued operations	—			18,829			17			—			18,846
Long-term debt, notes and convertible debentures	1,405,628			13,191			—			—			1,418,819
Deferred income tax liabilities	363,240			635,640			13,907			(54		)	1,012,733
Other noncurrent liabilities	—			52,072			1,763			—			53,835
Noncurrent liabilities of discontinued operations	—			1,398			—			—			1,398
Convertible debt	331,101			—			—			—			331,101
Stockholders' equity	2,740,803			4,778,727			352,553			(5,131,280		)	2,740,803
Total liabilities and stockholders' equity	$	5,451,004		$	6,293,318		$	392,226		$	(5,444,702	)	$	6,691,846
Note 10 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Statements of Cash Flows
(in thousands)
	Three months ended March 31,
2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(1,854	)	$	178,130		$	1,222		$	177,498
Cash flows from investing activities:
Divestiture of businesses, net	—			3,629			—			3,629
Capital expenditures	—			(25,702		)	(463		)	(26,165		)
Other	—			(284		)	—			(284		)
Net cash flows (used in) investing activities	—			(22,357		)	(463		)	(22,820		)
Cash flows from financing activities:
Payments on terms loans	(5,313		)	—			—			(5,313		)
Payments on long-term borrowings and obligations	(39,030		)	—			—			(39,030		)
Decrease in cash overdraft balance	(2,611		)	(926		)	—			(3,537		)
Payments for Omnicare common stock repurchase	(95,417		)	—			—			(95,417		)
Dividends paid	(19,596		)	—			—			(19,596		)
Other	172,321			(167,504		)	—			4,817
Net cash flows from (used in) financing activities	10,354			(168,430		)	—			(158,076		)
Net increase (decrease) in cash and cash equivalents	8,500			(12,657		)	759			(3,398		)
Increase (decrease) from discontinued operations	—			5,616			—			5,616
Net increase (decrease) from continuing operations	8,500			(18,273		)	759			(9,014		)
Cash and cash equivalents at beginning of period	275,910			68,050			12,041			356,001
Cash and cash equivalents at end of period	$	284,410		$	49,777		$	12,800		$	346,987
2013:00:00
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(3,365	)	$	114,407		$	(2,147	)	$	108,895
Cash flows from investing activities:
Capital expenditures	—			(22,099		)	(316		)	(22,415		)
Other	(227		)	367			—			140
Net cash flows used in investing activities	(227		)	(21,732		)	(316		)	(22,275		)
Cash flows from financing activities:
Payments on term loans	(5,313		)	—			—			(5,313		)
Payments on long-term borrowings and obligations	(1,684		)	—			—			(1,684		)
Increase (decrease) in cash overdraft balance	(10,900		)	1,126			—			(9,774		)
Payments for Omnicare common stock repurchases	(302		)	—			—			(302		)
Dividends paid	(14,479		)	—			—			(14,479		)
Other	89,860			(89,323		)	—			537
Net cash flows from (used in) financing activities	57,182			(88,197		)	—			(31,015		)
Net increase (decrease) in cash and cash equivalents	53,590			4,478			(2,463		)	55,605
Increase (decrease) from discontinued operations	—			1,717			—			1,717
Net increase (decrease) from continuing operations	53,590			2,761			(2,463		)	53,888
Cash and cash equivalents at beginning of period	383,674			49,108			11,838			444,620
Cash and cash equivalents at end of period	$	437,264		$	51,869		$	9,375		$	498,508
Note 10 - Guarantor Subsidiaries (Continued)
The Company’s 3.25% Convertible Senior Debentures due 2035 (with optional redemption by Omnicare on or after, or an optional repurchase right of holders on, December 15, 2015, at par) are fully and unconditionally guaranteed, subject to certain customary release provisions, on an unsecured basis by Omnicare Purchasing Company, LP, a wholly-owned subsidiary of the Company (the “Guarantor Subsidiary”).  The following condensed consolidating unaudited financial data illustrates the composition of Omnicare, Inc. (“Parent”), the Guarantor Subsidiary and the Non-Guarantor Subsidiaries as of March 31, 2014 and December 31, 2013 for the balance sheets, as well as the three months ended March 31, 2014 and 2013 for the statements of comprehensive income (loss) and the statements of cash flows.  Management believes separate complete financial statements of the Guarantor Subsidiary would not provide information that would be necessary for evaluating the sufficiency of the Guarantor Subsidiary, and thus are not presented.  The Guarantor Subsidiary does not have any material net cash flows in the condensed consolidating statements of cash flows.  The equity method has been used with respect to the Parent company’s investment in subsidiaries.  No consolidating/eliminating adjustments column is presented for the condensed consolidating statements of cash flows since there were no significant consolidating/eliminating adjustment amounts during the periods presented.
Summary Consolidating
Statements of Comprehensive Income (Loss)
(in thousands)
	For the three months ended March 31,
2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
										Eliminating Adjustments
Net sales	$	—		$	—		$	1,571,038		$	—		$	1,571,038
Cost of sales	—			—			1,212,584			—			1,212,584
Gross profit	—			—			358,454			—			358,454
Selling, general and administrative expenses	987			436			185,390			—			186,813
Provision for doubtful accounts	—			—			21,561			—			21,561
Settlement, litigation and other related charges	—			—			7,052			—			7,052
Other charges	—			—			10,276			—			10,276
Operating income (loss)	(987		)	(436		)	134,175			—			132,752
Interest expense, net of investment income	(29,156		)	—			(285		)	—			(29,441		)
Income (loss) before income taxes	(30,143		)	(436		)	133,890			—			103,311
Income tax (benefit) expense	(11,671		)	(169		)	51,513			—			39,673
Income (loss) from continuing operations	(18,472		)	(267		)	82,377			—			63,638
Income from discontinued operations	—			—			136			—			136
Equity of net income of subsidiaries	82,246			—			—			(82,246		)	—
Net income (loss)	$	63,774		$	(267	)	$	82,513		$	(82,246	)	$	63,774
Comprehensive income (loss)	$	63,997		$	(267	)	$	82,513		$	(82,246	)	$	63,997
2013:00:00
Net sales	$	—		$	—		$	1,458,945		$	—		$	1,458,945
Cost of sales	—			—			1,109,241			—			1,109,241
Gross profit	—			—			349,704			—			349,704
Selling, general and administrative expenses	1,006			399			189,288			—			190,693
Provision for doubtful accounts	—			—			24,010			—			24,010
Settlement, litigation and other related charges	—			—			22,619			—			22,619
Other charges	—			—			4,006			—			4,006
Operating income (loss)	(1,006		)	(399		)	109,781			—			108,376
Interest expense, net of investment income	(28,991		)	—			(471		)	—			(29,462		)
Income (loss) before income taxes	(29,997		)	(399		)	109,310			—			78,914
Income tax (benefit) expense	(11,546		)	(154		)	42,300			—			30,600
Income (loss) from continuing operations	(18,451		)	(245		)	67,010			—			48,314
Income from discontinued operations	—			—			6,040			—			6,040
Equity of net income of subsidiaries	72,805			—			—			(72,805		)	—
Net income (loss)	$	54,354		$	(245	)	$	73,050		$	(72,805	)	$	54,354
Comprehensive income (loss)	$	54,330		$	(245	)	$	73,050		$	(72,805	)	$	54,330
Note 10 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Balance Sheets
(in thousands)
As of March 31, 2014:	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	284,410		$	—		$	62,577		$	—		$	346,987
Accounts receivable, net (including intercompany)	—			188			755,620			(188		)	755,620
Inventories	—			—			442,634			—			442,634
Deferred income tax benefits, net-current	—			—			126,738			—			126,738
Other current assets	1,407			—			275,706			—			277,113
Current assets of discontinued operations	—			—			46,659			—			46,659
Total current assets	285,817			188			1,709,934			(188		)	1,995,751
Properties and equipment, net	—			17			317,839			—			317,856
Goodwill	—			—			4,057,456			—			4,057,456
Identifiable intangible assets, net	—			—			122,057			—			122,057
Other noncurrent assets	42,079			19			53,901			—			95,999
Noncurrent assets of discontinued operations	—			—			85,059			—			85,059
Investment in subsidiaries	5,059,898			—			—			(5,059,898		)	—
Total assets	$	5,387,794		$	224		$	6,346,246		$	(5,060,086	)	$	6,674,178
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities (including intercompany)	$	37,402		$	—		$	547,178		$	(188	)	$	584,392
Current portion of long term debt	528,475			—			—			—			528,475
Current liabilities of discontinued operations	—			—			17,407			—			17,407
Long-term debt, notes and convertible debentures	1,405,876			—			11,615			—			1,417,491
Deferred income tax liabilities	368,532			—			654,883			—			1,023,415
Other noncurrent liabilities	—			—			54,649			—			54,649
Noncurrent liabilities of discontinued operations	—			—			840			—			840
Convertible debt	329,425			—			—			—			329,425
Stockholders' equity	2,718,084			224			5,059,674			(5,059,898		)	2,718,084
Total liabilities and stockholders' equity	$	5,387,794		$	224		$	6,346,246		$	(5,060,086	)	$	6,674,178
As of December 31, 2013:
ASSETS
Cash and cash equivalents	$	275,910		$	—		$	80,091		$	—		$	356,001
Accounts receivable, net (including intercompany)	—			210			695,684			(210		)	695,684
Inventories	—			—			512,418			—			512,418
Deferred income tax benefits, net-current	—			—			135,094			—			135,094
Other current assets	1,989			—			263,547			—			265,536
Current assets of discontinued operations	—			—			49,995			—			49,995
Total current assets	277,899			210			1,736,829			(210		)	2,014,728
Properties and equipment, net	—			19			305,869			—			305,888
Goodwill	—			—			4,057,456			—			4,057,456
Identifiable intangible assets, net	—			—			129,974			—			129,974
Other noncurrent assets	41,825			19			54,878			—			96,722
Noncurrent assets of discontinued operations	—			—			87,078			—			87,078
Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
Total assets	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities (including intercompany)	$	83,028		$	—		$	504,289		$	(210	)	$	587,107
Current portion of long term debt	527,204			—			—			—			527,204
Current liabilities of discontinued operations	—			—			18,846			—			18,846
Long-term debt, notes and convertible debentures	1,405,628			—			13,191			—			1,418,819
Deferred income tax liabilities	363,240			—			649,493			—			1,012,733
Other noncurrent liabilities	—			—			53,835			—			53,835
Noncurrent liabilities of discontinued operations	—			—			1,398			—			1,398
Convertible debt	331,101			—			—			—			331,101
Stockholders' equity	2,740,803			248			5,131,032			(5,131,280		)	2,740,803
Total liabilities and stockholders' equity	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
Note 10 - Guarantor Subsidiaries (Continued)
Condensed Consolidating Statements of Cash Flows - Unaudited
(in thousands)
	Three months ended March 31,
2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(1,854	)	$	—		$	179,352		$	177,498
Cash flows from investing activities:
Disposition of businesses	—			—			3,629			3,629
Capital expenditures	—			—			(26,165		)	(26,165		)
Other	—			—			(284		)	(284		)
Net cash flows used in investing activities	—			—			(22,820		)	(22,820		)
Cash flows from financing activities:
Payments on terms loans	(5,313		)	—			—			(5,313		)
Payments on long-term borrowings and obligations	(39,030		)	—			—			(39,030		)
Decrease in cash overdraft balance	(2,611		)	—			(926		)	(3,537		)
Payments for Omnicare common stock repurchase	(95,417		)	—			—			(95,417		)
Dividends paid	(19,596		)	—			—			(19,596		)
Other	172,321			—			(167,504		)	4,817
Net cash flows from (used in) financing activities	10,354			—			(168,430		)	(158,076		)
Net increase in cash and cash equivalents	8,500			—			(11,898		)	(3,398		)
Less increase in cash and cash equivalents of discontinued operations	—			—			5,616			5,616
Increase (decrease) in cash and cash equivalents of continuing operations	8,500			—			(17,514		)	(9,014		)
Cash and cash equivalents at beginning of period	275,910			—			80,091			356,001
Cash and cash equivalents at end of period	$	284,410		$	—		$	62,577		$	346,987
2013:00:00
Cash flows from operating activities:
Net cash flows (used in) from operating activities	$	(3,365	)	$	—		$	112,260		$	108,895
Cash flows from investing activities:
Capital expenditures	—			—			(22,415		)	(22,415		)
Other	(227		)	—			367			140
Net cash flows used in investing activities	(227		)	—			(22,048		)	(22,275		)
Cash flows from financing activities:
Payments on term loans	(5,313		)	—			—			(5,313		)
Payments on long-term borrowings and obligations	(1,684		)	—			—			(1,684		)
Increase (decrease) in cash overdraft balance	(10,900		)	—			1,126			(9,774		)
Payments for Omnicare common stock repurchases	(302		)	—			—			(302		)
Dividends paid	(14,479		)	—			—			(14,479		)
Other	89,860			—			(89,323		)	537
Net cash flows from (used in) financing activities	57,182			—			(88,197		)	(31,015		)
Net increase (decrease) in cash and cash equivalents	53,590			—			2,015			55,605
Less increase in cash and cash equivalents of discontinued operations	—			—			1,717			1,717
Increase in cash and cash equivalents of continuing operations	53,590			—			298			53,888
Cash and cash equivalents at beginning of period	383,674			—			60,946			444,620
Cash and cash equivalents at end of period	$	437,264		$	—		$	61,244		$	498,508

Significant_Accounting_Policie1

Significant Accounting Policies Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Option Indexed to Issuer's Equity, Description [Text Block]	'
	On April 2, 2012, the Company entered into capped call transactions with a counterparty, paying $48.1 million for the purchase of the capped calls, which were recorded as additional paid in capital. The capped call transactions are intended to reduce potential economic dilution upon conversion of the 3.75% Convertible Senior Subordinated Notes due 2042. The capped calls settle in tranches through March 2016, one of which settled in the first quarter of 2014. The adjusted strike price for the capped calls ranged from $40.96 to $41.05 and the adjusted cap price for the tranche settled in 2014 ranged from $56.75 to $56.88; the strike and cap prices adjust for the Company's dividend payments. The Company received approximately 0.6 million net shares upon settlement with a value of approximately $38 million.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	Stock-based compensation expense recognized in the Consolidated Statement of Comprehensive Income for stock options, restricted stock units, performance share units and stock awards totaled approximately $6 million and $5 million for the three months ended March 31, 2014 and 2013 respectively.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The quarterly effective tax rates are different than the federal statutory rate largely as a result of the impact of state and local income taxes and certain non-deductible charges.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable
	The following table is an aging of the Company’s gross accounts receivable (net of allowances for contractual adjustments), aged based on payment terms and categorized based on the three primary types of accounts receivable characteristics (in thousands):
	March 31, 2014	Current and 0-180 Days Past Due		181 Days and Over Past Due		Total
	Medicare (Part D and Part B), Medicaid and Third-Party payors	$	234,075	$	49,819	$	283,894
	Facility payors	357,955		132,088		490,043
	Private Pay payors	78,768		83,276		162,044
	Total gross accounts receivable	$	670,798	$	265,183	$	935,981
	December 31, 2013
	Medicare (Part D and Part B), Medicaid and Third-Party payors	$	195,544	$	67,791	$	263,335
	Facility payors	328,444		146,751		475,195
	Private Pay payors	75,655		84,101		159,756
	Total gross accounts receivable	$	599,643	$	298,643	$	898,286
Common Stock Repurchase Agreement [Policy Text Block]	'
	Common Stock Repurchase Program
	In the three months ended March 31, 2014, the Company repurchased approximately 1.6 million shares through its authorized share repurchase program at an aggregate cost of approximately $95 million, for a cumulative amount of approximately 26 million shares of common stock repurchased at an aggregate cost of approximately $945 million from the inception of the share repurchase programs in May 2010 through March 31, 2014. In the three months ended March 31, 2013, the Company did not repurchase any shares through authorized share repurchase programs. The Company had approximately $405 million of share repurchase authority remaining as of March 31, 2014, which expires on December 31, 2015.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The Company’s financial assets and liabilities, measured at fair value on a recurring basis, were as follows (in thousands):
							Based on
			Fair Value				Quoted Prices in Active Markets			Other Observable Inputs			Unobservable Inputs
							(Level 1)			(Level 2)			(Level 3)
	March 31, 2014
	Bond portfolio		$	25,167			$	—		$	25,167		$	—
	7.75% interest rate swap agreements - fair value hedge		19,766				—			19,766			—
	Derivatives		—				—			—			—
	Total		$	44,933			$	—		$	44,933		$	—
	December 31, 2013
	Bond portfolio		$	25,140			$	—		$	25,140		$	—
	7.75% interest rate swap agreements - fair value hedge		18,671				—			18,671			—
	Derivatives		—				—			—			—
	Total		$	43,811			$	—		$	43,811		$	—
Accounts Receivable [Table Text Block]	'
	The following table is an aging of the Company’s gross accounts receivable (net of allowances for contractual adjustments), aged based on payment terms and categorized based on the three primary types of accounts receivable characteristics (in thousands):
	March 31, 2014		Current and 0-180 Days Past Due				181 Days and Over Past Due			Total
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	234,075			$	49,819		$	283,894
	Facility payors		357,955				132,088			490,043
	Private Pay payors		78,768				83,276			162,044
	Total gross accounts receivable		$	670,798			$	265,183		$	935,981
	December 31, 2013
	Medicare (Part D and Part B), Medicaid and Third-Party payors		$	195,544			$	67,791		$	263,335
	Facility payors		328,444				146,751			475,195
	Private Pay payors		75,655				84,101			159,756
	Total gross accounts receivable		$	599,643			$	298,643		$	898,286
Accumulated other comprehensive income(loss) [Table Text Block]	'
	Accumulated other comprehensive income (loss) ("AOCI") by component and in the aggregate, follows (in thousands):
			March 31,				December 31, 2013
			2014
	Unrealized loss on fair value of investments		$	(539	)		$	(702	)
	Pension and postemployment benefits		(1,779		)		(1,839		)
	Total accumulated other comprehensive income (loss), net		$	(2,318	)		$	(2,541	)
Schedule of Other Nonoperating Expense, by Component [Table Text Block]	'
	Other Charges
	Other charges (on a pre-tax basis) consist of the following (in thousands):
		Three months ended
		March 31,
		2014				2013
	Separation and other costs	$	10,276			$	3,469
	Acquisition and other related costs	—				537
	Total - other charges	$	10,276			$	4,006
Offsetting Assets [Table Text Block]	'
	The Company has interest rate swap agreements (the "Interest Rate Swap Agreements") with multiple counterparties on its 7.75% Senior Subordinated Notes due 2020 (the "2020 Notes"), which are subject to this guidance. The following table presents the Interest Rate Swap Agreements offsetting securities as of March 31, 2014 and December 31, 2013
										Gross Amounts not offset in the statement of financial position
	Interest Rate Swaps as of:	Gross amount of recognized assets (liabilities)			Gross amount offset in the statement of financial position			Net amount of assets (liabilities) presented in the statement of financial position		Financial instruments		Cash collateral received			Net amount
	31-Mar-14
	Swap A	$	10,013		$	—		$	10,013	$	—	$	—		$	10,013
	Swap B	9,753			—			9,753		—		—			9,753
		$	19,766		$	—		$	19,766	$	—	$	—		$	19,766
	December 31, 2013
	Swap A	$	9,408		$	—		$	9,408	$	—	$	—		$	9,408
	Swap B	9,263			—			9,263		—		—			9,263
		$	18,671		$	—		$	18,671	$	—	$	—		$	18,671

Discontinued_operations_Tables

Discontinued operations (Tables)	3 Months Ended
	Mar. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		Three months ended March 31,
		2014			2013
	Net Sales
	Hospice	$	48,357		$	52,497
	Retail	10,170			13,561
	Net sales - total discontinued	58,527			66,058
	Income (loss) from operations, pretax
	Hospice	1,214			9,888
	Retail	(474		)	(114		)
	Income from operations - total discontinued, pretax	740			9,774
	Income tax (benefit) expense
	Hospice	776			3,783
	Retail	(172		)	(49		)
	Income tax expense - total discontinued	604			3,734
	Income (loss) from discontinued operations
	Hospice	438			6,105
	Retail	(302		)	(65		)
	Income (loss) from discontinued operations - total	$	136		$	6,040

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The fair value of the Company’s fixed-rate debt facilities, excluding the Interest Rate Swap Agreements, is based on quoted market prices (Level II) and is summarized as follows (in thousands):
	Fair Value of Financial Instruments
		March 31, 2014							December 31, 2013
	Financial Instrument	Book Value			Market Value				Book Value		Market Value
	7.75% senior subordinated notes, due 2020	$	400,000		$	430,300			$	400,000	$	435,800
	3.75% convertible senior subordinated notes, due 2025
	Carrying value	87,848			—				87,310
	Unamortized debt discount	44,527			—				45,098
	Principal amount	132,375			299,200				132,408		306,500
	4.00% junior subordinated convertible debentures, due 2033
	Carrying value	186,773			—				186,136
	Unamortized debt discount	120,349			—				121,017
	Principal amount	307,122			450,300				307,153		455,900
	3.25% convertible senior debentures, due 2035
	Carrying value	397,146			—				393,126
	Unamortized debt discount	30,354			—				34,374
	Principal amount	427,500			454,800				427,500		457,400
	3.75% convertible senior subordinated notes, due 2042
	Carrying value	225,465			—				225,014
	Unamortized debt discount	164,535			—				164,986
	Principal amount	390,000			582,600				390,000		592,800
	3.50% convertible senior subordinated notes, due 2044
	Carrying value	217,088			—				216,643
	Unamortized debt discount	207,162			—				207,607
	Principal amount	424,250			432,600				424,250		428,500
Summary of Debt	'
	(in thousands):
		March 31,			December 31,
		2014			2013
	Revolving loans, due 2017	$	—		$	—
	Senior term loan, due 2017	393,125			398,438
	7.75% senior subordinated notes, due 2020	400,000			400,000
	3.75% convertible senior subordinated notes, due 2025	132,375			132,408
	4.00% junior subordinated convertible debentures, due 2033	307,122			307,153
	3.25% convertible senior debentures, due 2035	427,500			427,500
	3.75% convertible senior subordinated notes, due 2042	390,000			390,000
	3.50% convertible senior subordinated notes, due 2044	424,250			424,250
	Capitalized lease and other debt obligations	18,755			20,685
	Subtotal	2,493,127			2,500,434
	Add interest rate swap agreements	19,766			18,671
	(Subtract) unamortized debt discount	(566,927		)	(573,082		)
	(Subtract) current portion of debt	(528,475		)	(527,204		)
	Total long-term debt, net	$	1,417,491		$	1,418,819
Convertible debt and related equity	'
	Information relating to the Company's convertible securities at March 31, 2014 is in the following table:
	Convertible Debt	Carrying Value of Equity Component (in thousands)			Remaining Amortization Period		Effective Interest Rate
	3.75% convertible senior subordinated notes, due 2025	$	11,437		11.75		8.25	%
	4.00% junior subordinated convertible debentures, due 2033	$	118,348		19.25		8.01	%
	3.25% convertible senior debentures, due 2035	$	245,433		1.75		7.63	%
	3.75% convertible senior subordinated notes, due 2042	$	167,941		28		7.3	%
	3.50% convertible senior subordinated notes, due 2044	$	208,200		29.9		7.7	%

Earnings_Loss_Per_Share_Data_T

Earnings (Loss) Per Share Data (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Weighted Average Stock Price to include additional shares in diluted share calculation [Table Text Block]	'
	The Company is required to include additional shares in its diluted shares outstanding calculation based on the treasury stock method when the average market price of a share of Omnicare stock on the New York Stock Exchange for the applicable period exceeds the following amounts:
	Convertible Debt	Price
	3.75% convertible senior subordinated notes, due 2025	$	26.84
	4.00% junior subordinated convertible debentures, due 2033	$	40.82
	3.25% convertible senior debentures, due 2035	$	77.88
	3.75% convertible senior subordinated notes, due 2042	$	41.05
	3.50% convertible senior subordinated notes, due 2044	$	70
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following is a reconciliation of the basic and diluted earnings per share (“EPS”) computations for both the numerator and denominator (in thousands, except per share data):
		Three months ended March 31,
	2014:00:00	Income (Numerator)		Common Shares(Denominator)	Per Common
					Share Amounts
	Basic EPS
	Income from continuing operations	$	63,638		$	0.65
	Income from discontinued operations	136			—
	Net income	$	63,774	98,566	$	0.65
	Effect of Dilutive Securities
	Convertible securities	66		8,463
	Stock options, units and awards	—		738
	Diluted EPS
	Income from continuing operations plus assumed conversions	$	63,704		$	0.59
	Income from discontinued operations	136			—
	Net income plus assumed conversions	$	63,840	107,767	$	0.59
		Three months ended March 31,
	2013:00:00	Income (Numerator)		Common Shares(Denominator)	Per Common
					Share Amounts
	Basic EPS
	Income from continuing operations	$	48,314		$	0.47
	Income from discontinued operations	6,040			0.06
	Net income	$	54,354	103,210	$	0.53
	Effect of Dilutive Securities
	Convertible securities	71		3,753
	Stock options, warrants, units and awards	—		503
	Diluted EPS
	Income from continuing operations plus assumed conversions	$	48,385		$	0.45
	Income from discontinued operations	6,040			0.06
	Net income plus assumed conversions	$	54,425	107,466	$	0.51

Segment_Information_Segment_De

Segment Information Segment Detail (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Information [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		For the three months ended March 31,
	2014:00:00	LTC			SCG			Corporate/Other			Consolidated
											Totals
	Net sales	$	1,191,253		$	379,672		$	113		$	1,571,038
	Depreciation and amortization expense	(17,471		)	(1,127		)	(15,138		)	(33,736		)
	Settlement, litigation and other related charges	(7,052		)	—			—			(7,052		)
	Other charges	(2,511		)	—			(7,765		)	(10,276		)
	Operating income (loss)	152,584			31,729			(51,561		)	132,752
	2013:00:00
	Net sales	$	1,141,585		$	316,729		$	631		$	1,458,945
	Depreciation and amortization expense	(18,030		)	(1,103		)	(12,856		)	(31,989		)
	Settlement, litigation and other related charges	(22,619		)	—			—			(22,619		)
	Other charges	(2,752		)	—			(1,254		)	(4,006		)
	Operating income (loss)	129,817			28,109			(49,550		)	108,376

Guarantor_Subsidiaries_Tables

Guarantor Subsidiaries (Tables)	3 Months Ended
	Mar. 31, 2014
Guarantor Subsidiaries [Abstract]	'
Summary Consolidating Statements of Income (Guaranteed Senior Notes Payable)	'
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the three months ended March 31,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	1,540,006		$	31,032		$	—		$	1,571,038
	Cost of sales	—			1,194,399			18,185			—			1,212,584
	Gross profit	—			345,607			12,847			—			358,454
	Selling, general and administrative expenses	987			182,120			3,706			—			186,813
	Provision for doubtful accounts	—			21,047			514			—			21,561
	Settlement, litigation and other related charges	—			7,052			—			—			7,052
	Other charges	—			10,276			—			—			10,276
	Operating income (loss)	(987		)	125,112			8,627			—			132,752
	Interest expense, net of investment income	(29,156		)	(285		)	—			—			(29,441		)
	Income (loss) before income taxes	(30,143		)	124,827			8,627			—			103,311
	Income tax (benefit) expense	(11,671		)	48,004			3,340			—			39,673
	Income (loss) from continuing operations	(18,472		)	76,823			5,287			—			63,638
	Income (loss) from discontinued operations	—			171			(35		)	—			136
	Equity of net income of subsidiaries	82,246			—			—			(82,246		)	—
	Net income	$	63,774		$	76,994		$	5,252		$	(82,246	)	$	63,774
	Comprehensive income	$	63,997		$	76,994		$	5,252		$	(82,246	)	$	63,997
	2013:00:00
	Net sales	$	—		$	1,427,130		$	31,815		$	—		$	1,458,945
	Cost of sales	—			1,091,162			18,079			—			1,109,241
	Gross profit	—			335,968			13,736			—			349,704
	Selling, general and administrative expenses	1,006			184,978			4,709			—			190,693
	Provision for doubtful accounts	—			23,532			478			—			24,010
	Settlement, litigation and other related charges	—			22,619			—			—			22,619
	Other charges	—			4,006			—			—			4,006
	Operating income (loss)	(1,006		)	100,833			8,549			—			108,376
	Interest expense, net of investment income	(28,991		)	(293		)	(178		)	—			(29,462		)
	Income (loss) before income taxes	(29,997		)	100,540			8,371			—			78,914
	Income tax (benefit) expense	(11,546		)	38,924			3,222			—			30,600
	Income (loss) from continuing operations	(18,451		)	61,616			5,149			—			48,314
	Income (loss) from discontinued operations	—			6,063			(23		)	—			6,040
	Equity of net income of subsidiaries	72,805			—			—			(72,805		)	—
	Net income	$	54,354		$	67,679		$	5,126		$	(72,805	)	$	54,354
	Comprehensive income	$	54,330		$	67,679		$	5,126		$	(72,805	)	$	54,330
Condensed Consolidating Balance Sheets (Guaranteed Senior Notes Payable)	'
	Condensed Consolidating Balance Sheets
	(in thousands)
	As of March 31, 2014:	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
	ASSETS
	Cash and cash equivalents	$	284,410		$	49,777		$	12,800		$	—		$	346,987
	Accounts receivable, net (including intercompany)	—			752,924			336,511			(333,815		)	755,620
	Inventories	—			435,847			6,787			—			442,634
	Deferred income tax benefits, net-current	—			126,717			21			—			126,738
	Other current assets	1,407			250,744			24,962			—			277,113
	Current assets of discontinued operations	—			46,537			122			—			46,659
	Total current assets	285,817			1,662,546			381,203			(333,815		)	1,995,751
	Properties and equipment, net	—			313,016			4,840			—			317,856
	Goodwill	—			4,028,651			28,805			—			4,057,456
	Identifiable intangible assets, net	—			120,093			1,964			—			122,057
	Other noncurrent assets	42,079			53,855			65			—			95,999
	Noncurrent assets of discontinued operations	—			85,028			31			—			85,059
	Investment in subsidiaries	5,059,898			—			—			(5,059,898		)	—
	Total assets	$	5,387,794		$	6,263,189		$	416,908		$	(5,393,713	)	$	6,674,178
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities (including intercompany)	$	37,402		$	852,060		$	28,745		$	(333,815	)	$	584,392
	Current portion of long term debt	528,475			—			—			—			528,475
	Current liabilities of discontinued operations	—			17,404			3			—			17,407
	Long-term debt, notes and convertible debentures	1,405,876			11,615			—			—			1,417,491
	Deferred income tax liabilities	368,532			640,955			13,928			—			1,023,415
	Other noncurrent liabilities	—			52,960			1,689			—			54,649
	Noncurrent liabilities of discontinued operations	—			840			—			—			840
	Convertible debt	329,425			—			—			—			329,425
	Stockholders' equity	2,718,084			4,687,355			372,543			(5,059,898		)	2,718,084
	Total liabilities and stockholders' equity	$	5,387,794		$	6,263,189		$	416,908		$	(5,393,713	)	$	6,674,178
	As of December 31, 2013:
	ASSETS
	Cash and cash equivalents	$	275,910		$	68,050		$	12,041		$	—		$	356,001
	Accounts receivable, net (including intercompany)	—			693,729			315,323			(313,368		)	695,684
	Inventories	—			505,567			6,851			—			512,418
	Deferred income tax benefits, net-current	—			135,148			—			(54		)	135,094
	Other current assets	1,989			242,166			21,381			—			265,536
	Current assets of discontinued operations	—			49,128			867			—			49,995
	Total current assets	277,899			1,693,788			356,463			(313,422		)	2,014,728
	Properties and equipment, net	—			301,200			4,688			—			305,888
	Goodwill	—			4,028,651			28,805			—			4,057,456
	Identifiable intangible assets, net	—			127,798			2,176			—			129,974
	Other noncurrent assets	41,825			54,834			63			—			96,722
	Noncurrent assets of discontinued operations	—			87,047			31			—			87,078
	Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
	Total assets	$	5,451,004		$	6,293,318		$	392,226		$	(5,444,702	)	$	6,691,846
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities (including intercompany)	$	83,028		$	793,461		$	23,986		$	(313,368	)	$	587,107
	Current portion of long term debt	527,204			—			—			—			527,204
	Current liabilities of discontinued operations	—			18,829			17			—			18,846
	Long-term debt, notes and convertible debentures	1,405,628			13,191			—			—			1,418,819
	Deferred income tax liabilities	363,240			635,640			13,907			(54		)	1,012,733
	Other noncurrent liabilities	—			52,072			1,763			—			53,835
	Noncurrent liabilities of discontinued operations	—			1,398			—			—			1,398
	Convertible debt	331,101			—			—			—			331,101
	Stockholders' equity	2,740,803			4,778,727			352,553			(5,131,280		)	2,740,803
	Total liabilities and stockholders' equity	$	5,451,004		$	6,293,318		$	392,226		$	(5,444,702	)	$	6,691,846
Condensed Consolidating Statements of Cash Flows (Guaranteed Senior Notes Payable)	'
	Condensed Consolidating Statements of Cash Flows
	(in thousands)
		Three months ended March 31,
	2014:00:00	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(1,854	)	$	178,130		$	1,222		$	177,498
	Cash flows from investing activities:
	Divestiture of businesses, net	—			3,629			—			3,629
	Capital expenditures	—			(25,702		)	(463		)	(26,165		)
	Other	—			(284		)	—			(284		)
	Net cash flows (used in) investing activities	—			(22,357		)	(463		)	(22,820		)
	Cash flows from financing activities:
	Payments on terms loans	(5,313		)	—			—			(5,313		)
	Payments on long-term borrowings and obligations	(39,030		)	—			—			(39,030		)
	Decrease in cash overdraft balance	(2,611		)	(926		)	—			(3,537		)
	Payments for Omnicare common stock repurchase	(95,417		)	—			—			(95,417		)
	Dividends paid	(19,596		)	—			—			(19,596		)
	Other	172,321			(167,504		)	—			4,817
	Net cash flows from (used in) financing activities	10,354			(168,430		)	—			(158,076		)
	Net increase (decrease) in cash and cash equivalents	8,500			(12,657		)	759			(3,398		)
	Increase (decrease) from discontinued operations	—			5,616			—			5,616
	Net increase (decrease) from continuing operations	8,500			(18,273		)	759			(9,014		)
	Cash and cash equivalents at beginning of period	275,910			68,050			12,041			356,001
	Cash and cash equivalents at end of period	$	284,410		$	49,777		$	12,800		$	346,987
	2013:00:00
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(3,365	)	$	114,407		$	(2,147	)	$	108,895
	Cash flows from investing activities:
	Capital expenditures	—			(22,099		)	(316		)	(22,415		)
	Other	(227		)	367			—			140
	Net cash flows used in investing activities	(227		)	(21,732		)	(316		)	(22,275		)
	Cash flows from financing activities:
	Payments on term loans	(5,313		)	—			—			(5,313		)
	Payments on long-term borrowings and obligations	(1,684		)	—			—			(1,684		)
	Increase (decrease) in cash overdraft balance	(10,900		)	1,126			—			(9,774		)
	Payments for Omnicare common stock repurchases	(302		)	—			—			(302		)
	Dividends paid	(14,479		)	—			—			(14,479		)
	Other	89,860			(89,323		)	—			537
	Net cash flows from (used in) financing activities	57,182			(88,197		)	—			(31,015		)
	Net increase (decrease) in cash and cash equivalents	53,590			4,478			(2,463		)	55,605
	Increase (decrease) from discontinued operations	—			1,717			—			1,717
	Net increase (decrease) from continuing operations	53,590			2,761			(2,463		)	53,888
	Cash and cash equivalents at beginning of period	383,674			49,108			11,838			444,620
	Cash and cash equivalents at end of period	$	437,264		$	51,869		$	9,375		$	498,508
Summary Consolidating Statements of Income (Guaranteed Convertible Senior Debentures)	'
	Summary Consolidating
	Statements of Comprehensive Income (Loss)
	(in thousands)
		For the three months ended March 31,
	2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating /			Omnicare, Inc. and Subsidiaries
											Eliminating Adjustments
	Net sales	$	—		$	—		$	1,571,038		$	—		$	1,571,038
	Cost of sales	—			—			1,212,584			—			1,212,584
	Gross profit	—			—			358,454			—			358,454
	Selling, general and administrative expenses	987			436			185,390			—			186,813
	Provision for doubtful accounts	—			—			21,561			—			21,561
	Settlement, litigation and other related charges	—			—			7,052			—			7,052
	Other charges	—			—			10,276			—			10,276
	Operating income (loss)	(987		)	(436		)	134,175			—			132,752
	Interest expense, net of investment income	(29,156		)	—			(285		)	—			(29,441		)
	Income (loss) before income taxes	(30,143		)	(436		)	133,890			—			103,311
	Income tax (benefit) expense	(11,671		)	(169		)	51,513			—			39,673
	Income (loss) from continuing operations	(18,472		)	(267		)	82,377			—			63,638
	Income from discontinued operations	—			—			136			—			136
	Equity of net income of subsidiaries	82,246			—			—			(82,246		)	—
	Net income (loss)	$	63,774		$	(267	)	$	82,513		$	(82,246	)	$	63,774
	Comprehensive income (loss)	$	63,997		$	(267	)	$	82,513		$	(82,246	)	$	63,997
	2013:00:00
	Net sales	$	—		$	—		$	1,458,945		$	—		$	1,458,945
	Cost of sales	—			—			1,109,241			—			1,109,241
	Gross profit	—			—			349,704			—			349,704
	Selling, general and administrative expenses	1,006			399			189,288			—			190,693
	Provision for doubtful accounts	—			—			24,010			—			24,010
	Settlement, litigation and other related charges	—			—			22,619			—			22,619
	Other charges	—			—			4,006			—			4,006
	Operating income (loss)	(1,006		)	(399		)	109,781			—			108,376
	Interest expense, net of investment income	(28,991		)	—			(471		)	—			(29,462		)
	Income (loss) before income taxes	(29,997		)	(399		)	109,310			—			78,914
	Income tax (benefit) expense	(11,546		)	(154		)	42,300			—			30,600
	Income (loss) from continuing operations	(18,451		)	(245		)	67,010			—			48,314
	Income from discontinued operations	—			—			6,040			—			6,040
	Equity of net income of subsidiaries	72,805			—			—			(72,805		)	—
	Net income (loss)	$	54,354		$	(245	)	$	73,050		$	(72,805	)	$	54,354
	Comprehensive income (loss)	$	54,330		$	(245	)	$	73,050		$	(72,805	)	$	54,330
Condensed Consolidating Balance Sheets (Guaranteed Convertible Senior Debentures)	'
	Condensed Consolidating Balance Sheets
	(in thousands)
	As of March 31, 2014:	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Consolidating/Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
	ASSETS
	Cash and cash equivalents	$	284,410		$	—		$	62,577		$	—		$	346,987
	Accounts receivable, net (including intercompany)	—			188			755,620			(188		)	755,620
	Inventories	—			—			442,634			—			442,634
	Deferred income tax benefits, net-current	—			—			126,738			—			126,738
	Other current assets	1,407			—			275,706			—			277,113
	Current assets of discontinued operations	—			—			46,659			—			46,659
	Total current assets	285,817			188			1,709,934			(188		)	1,995,751
	Properties and equipment, net	—			17			317,839			—			317,856
	Goodwill	—			—			4,057,456			—			4,057,456
	Identifiable intangible assets, net	—			—			122,057			—			122,057
	Other noncurrent assets	42,079			19			53,901			—			95,999
	Noncurrent assets of discontinued operations	—			—			85,059			—			85,059
	Investment in subsidiaries	5,059,898			—			—			(5,059,898		)	—
	Total assets	$	5,387,794		$	224		$	6,346,246		$	(5,060,086	)	$	6,674,178
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities (including intercompany)	$	37,402		$	—		$	547,178		$	(188	)	$	584,392
	Current portion of long term debt	528,475			—			—			—			528,475
	Current liabilities of discontinued operations	—			—			17,407			—			17,407
	Long-term debt, notes and convertible debentures	1,405,876			—			11,615			—			1,417,491
	Deferred income tax liabilities	368,532			—			654,883			—			1,023,415
	Other noncurrent liabilities	—			—			54,649			—			54,649
	Noncurrent liabilities of discontinued operations	—			—			840			—			840
	Convertible debt	329,425			—			—			—			329,425
	Stockholders' equity	2,718,084			224			5,059,674			(5,059,898		)	2,718,084
	Total liabilities and stockholders' equity	$	5,387,794		$	224		$	6,346,246		$	(5,060,086	)	$	6,674,178
	As of December 31, 2013:
	ASSETS
	Cash and cash equivalents	$	275,910		$	—		$	80,091		$	—		$	356,001
	Accounts receivable, net (including intercompany)	—			210			695,684			(210		)	695,684
	Inventories	—			—			512,418			—			512,418
	Deferred income tax benefits, net-current	—			—			135,094			—			135,094
	Other current assets	1,989			—			263,547			—			265,536
	Current assets of discontinued operations	—			—			49,995			—			49,995
	Total current assets	277,899			210			1,736,829			(210		)	2,014,728
	Properties and equipment, net	—			19			305,869			—			305,888
	Goodwill	—			—			4,057,456			—			4,057,456
	Identifiable intangible assets, net	—			—			129,974			—			129,974
	Other noncurrent assets	41,825			19			54,878			—			96,722
	Noncurrent assets of discontinued operations	—			—			87,078			—			87,078
	Investment in subsidiaries	5,131,280			—			—			(5,131,280		)	—
	Total assets	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
	LIABILITIES AND STOCKHOLDERS' EQUITY
	Current liabilities (including intercompany)	$	83,028		$	—		$	504,289		$	(210	)	$	587,107
	Current portion of long term debt	527,204			—			—			—			527,204
	Current liabilities of discontinued operations	—			—			18,846			—			18,846
	Long-term debt, notes and convertible debentures	1,405,628			—			13,191			—			1,418,819
	Deferred income tax liabilities	363,240			—			649,493			—			1,012,733
	Other noncurrent liabilities	—			—			53,835			—			53,835
	Noncurrent liabilities of discontinued operations	—			—			1,398			—			1,398
	Convertible debt	331,101			—			—			—			331,101
	Stockholders' equity	2,740,803			248			5,131,032			(5,131,280		)	2,740,803
	Total liabilities and stockholders' equity	$	5,451,004		$	248		$	6,372,084		$	(5,131,490	)	$	6,691,846
Condensed Consolidating Statements of Cash Flows (Guaranteed Convertible Senior Debentures)	'
	Condensed Consolidating Statements of Cash Flows - Unaudited
	(in thousands)
		Three months ended March 31,
	2014:00:00	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(1,854	)	$	—		$	179,352		$	177,498
	Cash flows from investing activities:
	Disposition of businesses	—			—			3,629			3,629
	Capital expenditures	—			—			(26,165		)	(26,165		)
	Other	—			—			(284		)	(284		)
	Net cash flows used in investing activities	—			—			(22,820		)	(22,820		)
	Cash flows from financing activities:
	Payments on terms loans	(5,313		)	—			—			(5,313		)
	Payments on long-term borrowings and obligations	(39,030		)	—			—			(39,030		)
	Decrease in cash overdraft balance	(2,611		)	—			(926		)	(3,537		)
	Payments for Omnicare common stock repurchase	(95,417		)	—			—			(95,417		)
	Dividends paid	(19,596		)	—			—			(19,596		)
	Other	172,321			—			(167,504		)	4,817
	Net cash flows from (used in) financing activities	10,354			—			(168,430		)	(158,076		)
	Net increase in cash and cash equivalents	8,500			—			(11,898		)	(3,398		)
	Less increase in cash and cash equivalents of discontinued operations	—			—			5,616			5,616
	Increase (decrease) in cash and cash equivalents of continuing operations	8,500			—			(17,514		)	(9,014		)
	Cash and cash equivalents at beginning of period	275,910			—			80,091			356,001
	Cash and cash equivalents at end of period	$	284,410		$	—		$	62,577		$	346,987
	2013:00:00
	Cash flows from operating activities:
	Net cash flows (used in) from operating activities	$	(3,365	)	$	—		$	112,260		$	108,895
	Cash flows from investing activities:
	Capital expenditures	—			—			(22,415		)	(22,415		)
	Other	(227		)	—			367			140
	Net cash flows used in investing activities	(227		)	—			(22,048		)	(22,275		)
	Cash flows from financing activities:
	Payments on term loans	(5,313		)	—			—			(5,313		)
	Payments on long-term borrowings and obligations	(1,684		)	—			—			(1,684		)
	Increase (decrease) in cash overdraft balance	(10,900		)	—			1,126			(9,774		)
	Payments for Omnicare common stock repurchases	(302		)	—			—			(302		)
	Dividends paid	(14,479		)	—			—			(14,479		)
	Other	89,860			—			(89,323		)	537
	Net cash flows from (used in) financing activities	57,182			—			(88,197		)	(31,015		)
	Net increase (decrease) in cash and cash equivalents	53,590			—			2,015			55,605
	Less increase in cash and cash equivalents of discontinued operations	—			—			1,717			1,717
	Increase in cash and cash equivalents of continuing operations	53,590			—			298			53,888
	Cash and cash equivalents at beginning of period	383,674			—			60,946			444,620
	Cash and cash equivalents at end of period	$	437,264		$	—		$	61,244		$	498,508

Significant_Accounting_Policie3

Significant Accounting Policies Stock Based Compensation expense (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Significant Accounting Policies [Abstract]	'	'
Allocated Share-based Compensation Expense	$6	$5

Significant_Accounting_Policie4

Significant Accounting Policies Accounts Receivable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Receivable, Gross, Current	$935,981	$898,286
Medicare Medicaid and Third Party Payors [Member]	'	'
Accounts Receivable, Gross, Current	283,894	263,335
Facility Payors [Member]	'	'
Accounts Receivable, Gross, Current	490,043	475,195
Private Payors [Member]	'	'
Accounts Receivable, Gross, Current	162,044	159,756
0 - 180 Days Past Due [Member]	'	'
Accounts Receivable, Gross, Current	670,798	599,643
0 - 180 Days Past Due [Member] | Medicare Medicaid and Third Party Payors [Member]	'	'
Accounts Receivable, Gross, Current	234,075	195,544
0 - 180 Days Past Due [Member] | Facility Payors [Member]	'	'
Accounts Receivable, Gross, Current	357,955	328,444
0 - 180 Days Past Due [Member] | Private Payors [Member]	'	'
Accounts Receivable, Gross, Current	78,768	75,655
181 Days and Greater Past Due [Member]	'	'
Accounts Receivable, Gross, Current	265,183	298,643
181 Days and Greater Past Due [Member] | Medicare Medicaid and Third Party Payors [Member]	'	'
Accounts Receivable, Gross, Current	49,819	67,791
181 Days and Greater Past Due [Member] | Facility Payors [Member]	'	'
Accounts Receivable, Gross, Current	132,088	146,751
181 Days and Greater Past Due [Member] | Private Payors [Member]	'	'
Accounts Receivable, Gross, Current	$83,276	$84,101

Significant_Accounting_Policie5

Significant Accounting Policies Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Unrealized (loss) gain on fair value of investments	($539)	($702)
Pension and postemployment benefits	-1,779	-1,839
Accumulated Other Comprehensive Income (Loss), Net of Tax	($2,318)	($2,541)

Significant_Accounting_Policie6

Significant Accounting Policies Fair Value (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Bond Portfolio at fair market value	$25,167	$25,140
Interest Rate Swap Agreement Fair Value Liability Disclosure	19,766	18,671
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	44,933	43,811
Fair Value, Inputs, Level 1 [Member]	'	'
Bond Portfolio at fair market value	0	0
Interest Rate Swap Agreement Fair Value Liability Disclosure	0	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Bond Portfolio at fair market value	25,167	25,140
Interest Rate Swap Agreement Fair Value Liability Disclosure	19,766	18,671
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	44,933	43,811
Fair Value, Inputs, Level 3 [Member]	'	'
Bond Portfolio at fair market value	0	0
Interest Rate Swap Agreement Fair Value Liability Disclosure	0	0
Derivative Financial Instruments, Liabilities, Fair Value Disclosure	0	0
Assets, Fair Value Disclosure	$0	$0

Significant_Accounting_Policie7

Significant Accounting Policies Offsetting Assets and Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deposits Paid for Securities Borrowed, at Carrying Value	$0	$0
Gross Amount of assets as Offset in Statement of Financial Position	0	0
Securities Borrowed	19,766	18,671
Financial Instruments, assets	0	0
Swap A [Member]	'	'
Deposits Paid for Securities Borrowed, at Carrying Value	0	0
Gross Amount of assets as Offset in Statement of Financial Position	0	0
Net amount of financial assets	10,013	9,408
Securities Borrowed	10,013	9,408
Financial Instruments, assets	0	0
Swap B [Member]	'	'
Deposits Paid for Securities Borrowed, at Carrying Value	0	0
Gross Amount of assets as Offset in Statement of Financial Position	0	0
Net amount of financial assets	9,753	9,263
Securities Borrowed	9,753	9,263
Financial Instruments, assets	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Interest Rate Swap Agreement Fair Value Disclosure	$19,766	$18,671

Significant_Accounting_Policie8

Significant Accounting Policies Other Charges (Credits) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Abstract]	'	'
Separation, Benefit Plan Termination and Related Costs	$10,276	$3,469
Acquisition Costs, Period Cost	0	537
Other charges	$10,276	$4,006

Significant_Accounting_Policie9

Significant Accounting Policies Restructuring and Other Related Charges (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring Reserve	$4	$5
Payments for Restructuring	-1	'
Employee Severance [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring reserve, cumulative payments through period	$3	'

Recovered_Sheet1

Significant Accounting Policies Common Stock Repurchase Program (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Significant Accounting Policies [Abstract]	'
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$405
cumulative value of shares repurchased through stock repurchase program	945
cumulative common stock repurchased through repurchase program	26
Stock Repurchased During Period, Value	$95
Stock Repurchased During Period, Shares	1.6

Recovered_Sheet2

Significant Accounting Policies Capped Call (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014
Shares received upon settlement of capped call	0.6
Economic value of shares received upon settlement of capped call	$38
Maximum [Member]	'
option indexed to Company's own stock - strike price	$41.05
Option indexed to Issuer's own equity, cap price	$56.88
Minimum [Member]	'
option indexed to Company's own stock - strike price	$40.96
Option indexed to Issuer's own equity, cap price	$56.75

Discontinued_operations_Detail

Discontinued operations (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Disposal Group, Including Discontinued Operation, Revenue	$58,527	$66,058
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	740	9,774
Disposal Group, Including Discontinued Operation, Income Tax Benefit	604	3,734
Disposal Group, Including Discontinued Operation, Operating Income (Loss), After tax	136	'
Hospice Disposal Group [Member] [Member]	'	'
Disposal Group, Including Discontinued Operation, Revenue	48,357	52,497
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	1,214	9,888
Disposal Group, Including Discontinued Operation, Income Tax Benefit	776	3,783
Disposal Group, Including Discontinued Operation, Operating Income (Loss), After tax	438	6,105
Retail Disposal Group [Member]	'	'
Disposal Group, Including Discontinued Operation, Revenue	10,170	13,561
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	-474	-114
Disposal Group, Including Discontinued Operation, Income Tax Benefit	-172	-49
Disposal Group, Including Discontinued Operation, Operating Income (Loss), After tax	($302)	($65)

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Goodwill [Line Items]	'	'	'
Goodwill	$4,057,456,000	'	$4,057,456,000
Intangible amortization expense	$8,000,000	$9,000,000	'

Debt_Details

Debt (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	$2,493,127,000	$2,500,434,000
stated liquidation amount of convertible debt	50	'
Interest rate swap agreements	19,766,000	18,671,000
Debt Instrument, Unamortized Discount	-566,927,000	-573,082,000
Debt, Current	-528,475,000	-527,204,000
Long-term Debt, Excluding Current Maturities	1,417,491,000	1,418,819,000
Debt Instrument, Interest Rate, Stated Percentage	7.75%	'
Letters of Credit Outstanding, Amount	14,000,000	'
Derivative, Basis Spread on Variable Rate	4.20%	'
Amortization of Financing Costs	1,000,000	'
Current Revolving Credit Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	0	0
Senior Term Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	393,125,000	398,438,000
Debt Instrument, Interest Rate, Stated Percentage	1.91%	'
7.75% Senior Subordinated Notes, Due 2020 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	400,000,000	400,000,000
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	132,375,000	132,408,000
Debt Instrument, Unamortized Discount	-44,527,000	-45,098,000
treasury stock method average share price to include dilutive securities	$26.84	'
conversion threshold	34.89	'
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	307,122,000	307,153,000
Debt instrument, convertible, contingent interest rate	0.13%	'
contingent cash interest paid per stated liquidation amount	0.09	'
contingent cash interest per stated liquidation amount	0.09	'
Debt Instrument, Unamortized Discount	-120,349,000	-121,017,000
treasury stock method average share price to include dilutive securities	$40.82	'
4.0% Junior Subordinated debt due 2033 [Domain]	'	'
Debt Instrument [Line Items]	'	'
conversion threshold	53.07	'
3.25% Convertible Senior Debentures, Due 2035 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	427,500,000	427,500,000
Debt Instrument, Unamortized Discount	-30,354,000	-34,374,000
treasury stock method average share price to include dilutive securities	$77.88	'
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	390,000,000	390,000,000
Debt Instrument, Unamortized Discount	-164,535,000	-164,986,000
treasury stock method average share price to include dilutive securities	$41.05	'
conversion threshold	53.37	'
3.5% Convertible senior subordinated debt [Domain]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	424,250,000	424,250,000
treasury stock method average share price to include dilutive securities	$70	'
Capitalized Lease and Other Debt Obligations [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	$18,755,000	$20,685,000

Debt_Schedule_of_Convertible_D

Debt Schedule of Convertible Debt (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Convertible, Carrying Amount of Equity Component	$11,437
Remaining amortization period for the debt discount (in years)	'11 years 274 days
Debt Instrument, Interest Rate, Effective Percentage	8.25%
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Convertible, Carrying Amount of Equity Component	118,348
Remaining amortization period for the debt discount (in years)	'19 years 91 days
Debt Instrument, Interest Rate, Effective Percentage	8.01%
3.25% Convertible Senior Debentures, Due 2035 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Convertible, Carrying Amount of Equity Component	245,433
Remaining amortization period for the debt discount (in years)	'1 year 274 days
Debt Instrument, Interest Rate, Effective Percentage	7.63%
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Convertible, Carrying Amount of Equity Component	167,941
Remaining amortization period for the debt discount (in years)	'28 years
Debt Instrument, Interest Rate, Effective Percentage	7.30%
3.5% Convertible senior subordinated debt [Domain]	'
Debt Instrument [Line Items]	'
Debt Instrument, Convertible, Carrying Amount of Equity Component	$208,200
Remaining amortization period for the debt discount (in years)	'29 years 329 days
Debt Instrument, Interest Rate, Effective Percentage	7.70%

Debt_Fair_Value_of_Financial_I

Debt Fair Value of Financial Instruments (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-term Debt, Gross	$2,493,127	$2,500,434
Debt Instrument, Unamortized Discount	566,927	573,082
7.75% Senior Subordinated Notes, Due 2020 [Member]	'	'
Long-term Debt, Gross	400,000	400,000
Long-term Debt, Fair Value	430,300	435,800
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'	'
Long-term Debt, Gross	132,375	132,408
Long-term Debt, Fair Value	299,200	306,500
Long-term Debt	87,848	87,310
Debt Instrument, Unamortized Discount	44,527	45,098
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'	'
Long-term Debt, Gross	307,122	307,153
Long-term Debt, Fair Value	450,300	455,900
Long-term Debt	186,773	186,136
Debt Instrument, Unamortized Discount	120,349	121,017
3.25% Convertible Senior Debentures, Due 2035 [Member]	'	'
Long-term Debt, Gross	427,500	427,500
Long-term Debt, Fair Value	454,800	457,400
Long-term Debt	397,146	393,126
Debt Instrument, Unamortized Discount	30,354	34,374
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'	'
Long-term Debt, Gross	390,000	390,000
Long-term Debt, Fair Value	582,600	592,800
Long-term Debt	225,465	225,014
Debt Instrument, Unamortized Discount	164,535	164,986
3.50% Convertible Senior Subordianted Notes, Due 2044 [Member]	'	'
Long-term Debt, Gross	424,250	424,250
Long-term Debt, Fair Value	432,600	428,500
Long-term Debt	217,088	216,643
Debt Instrument, Unamortized Discount	$207,162	$207,607

Earnings_Loss_Per_Share_Data_D

Earnings (Loss) Per Share Data (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Income (Loss) from Continuing Operations Attributable to Parent	$63,638	$48,314
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	63,774	54,354
Earnings (loss) per common share - Basic:	'	'
Net income	$0.65	$0.53
Effect of Dilutive Securities [Abstract]	'	'
Convertible Securities	66	71
Stock options, warrants and awards	0	0
Convertible Securities (in shares)	8,463,000	3,753,000
Stock options, warrants and awards, common shares (in shares)	738,000	503,000
Income from continuing operations plus assumed conversions	63,704	48,385
Earnings (loss) per common share - Diluted:	'	'
Net income plus assumed conversions	63,840	54,425
Diluted shares (in shares)	107,767,000	107,466,000
Diluted earnings per share (per share)	$0.59	$0.51
Aggregate number of stock options, warrants and awards excluded from the computation of diluted EPS (in shares)	'	2,000,000
Income (Loss) from Continuing Operations, Per Basic Share	$0.65	$0.47
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$136	$6,040
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	$0	$0.06
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	$0	$0.06
Income (Loss) from Continuing Operations, Per Diluted Share	$0.59	$0.45
Weighted Average Number of Shares Outstanding, Basic	98,566,000	103,210,000

EarningsPer_Share_Data_Convert

EarningsPer Share Data Convertible Debt (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
3.75% Convertible Senior Subordinated Notes, due 2025 [Member]	'
treasury stock method average share price to include dilutive securities	$26.84
4.00% Junior Subordinated Convertible Debentures, due 2033 [Member]	'
treasury stock method average share price to include dilutive securities	$40.82
3.25% Convertible Senior Debentures, Due 2035 [Member]	'
treasury stock method average share price to include dilutive securities	$77.88
3.75% Convertible Senior Subordinated Notes Due 2042 [Member]	'
treasury stock method average share price to include dilutive securities	$41.05
3.5% Convertible senior subordinated debt [Domain]	'
treasury stock method average share price to include dilutive securities	$70

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Settlement, litigation and other related charges	$7,052	$22,619

Segment_Information_Segment_In

Segment Information Segment Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenue, Net	$1,571,038	$1,458,945
Depreciation and amortization expense	-33,736	-31,989
Settlements, litigations and other related charges	-7,052	-22,619
Other charges	-10,276	-4,006
Operating Income (Loss)	132,752	108,376
Long Term Care Group [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue, Net	1,191,253	1,141,585
Depreciation and amortization expense	-17,471	-18,030
Settlements, litigations and other related charges	-7,052	-22,619
Other charges	-2,511	-2,752
Operating Income (Loss)	152,584	129,817
specialty care group [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue, Net	379,672	316,729
Depreciation and amortization expense	-1,127	-1,103
Settlements, litigations and other related charges	0	0
Other charges	0	0
Operating Income (Loss)	31,729	28,109
Corporate/Other [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue, Net	113	631
Depreciation and amortization expense	-15,138	-12,856
Settlements, litigations and other related charges	0	0
Other charges	-7,765	-1,254
Operating Income (Loss)	($51,561)	($49,550)

Guarantor_Subsidiaries_Details

Guarantor Subsidiaries (Details) (USD $)	3 Months Ended				3 Months Ended			3 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended					3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Sep. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2012	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2012	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
					Parent Company [Member]	Parent Company [Member]	Parent Company [Member]	Guarantor Subsidiaries [Member]	Guarantor Subsidiaries [Member]	Guarantor Subsidiaries [Member]	Guarantor Subsidiaries [Member]	Guarantor Subsidiaries [Member]	Guarantor Subsidiaries [Member]	Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Non-Guarantor Subsidiaries [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]	Consolidating, Eliminating Adjustments [Member]
								Convertible Senior Debentures [Member]	Convertible Senior Debentures [Member]	Convertible Senior Debentures [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]	Convertible Senior Debentures [Member]	Convertible Senior Debentures [Member]	Convertible Senior Debentures [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]			Convertible Senior Debentures [Member]	Convertible Senior Debentures [Member]	Convertible Senior Debentures [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]	Guaranteed Senior Notes Payable [Member]
Summary Consolidating Statements of Income [Abstract]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net sales	$1,571,038	$1,458,945	'	'	$0	$0	'	$0	$0	'	$1,540,006	$1,427,130	'	'	$1,571,038	$1,458,945	'	$31,032	$31,815	'	'	'	'	$0	$0	'	$0	$0	'
Cost of sales	1,212,584	1,109,241	'	'	0	0	'	0	0	'	1,194,399	1,091,162	'	'	1,212,584	1,109,241	'	18,185	18,079	'	'	'	'	0	0	'	0	0	'
Gross profit	358,454	349,704	'	'	0	0	'	0	0	'	345,607	335,968	'	'	358,454	349,704	'	12,847	13,736	'	'	'	'	0	0	'	0	0	'
Selling, general and administrative expenses	186,813	190,693	'	'	987	1,006	'	436	399	'	182,120	184,978	'	'	185,390	189,288	'	3,706	4,709	'	'	'	'	0	0	'	0	0	'
Provision for doubtful accounts	21,561	24,010	'	'	0	0	'	0	0	'	21,047	23,532	'	'	21,561	24,010	'	514	478	'	'	'	'	0	0	'	0	0	'
Settlement, litigation and other related charges	7,052	22,619	'	'	0	0	'	0	0	'	7,052	22,619	'	'	7,052	22,619	'	0	0	'	'	'	'	0	0	'	0	0	'
Other miscellaneous charges	10,276	4,006	'	'	0	0	'	0	0	'	10,276	4,006	'	'	10,276	4,006	'	0	0	'	'	'	'	0	0	'	0	0	'
Operating income	132,752	108,376	'	'	-987	-1,006	'	-436	-399	'	125,112	100,833	'	'	134,175	109,781	'	8,627	8,549	'	'	'	'	0	0	'	0	0	'
Interest expense, net of investment income	-29,441	-29,462	'	'	-29,156	-28,991	'	0	0	'	-285	-293	'	'	-285	-471	'	0	-178	'	'	'	'	0	0	'	0	0	'
Income before income taxes	103,311	78,914	'	'	-30,143	-29,997	'	-436	-399	'	124,827	100,540	'	'	133,890	109,310	'	8,627	8,371	'	'	'	'	0	0	'	0	0	'
Income tax (benefit) expense	39,673	30,600	'	'	-11,671	-11,546	'	-169	-154	'	48,004	38,924	'	'	51,513	42,300	'	3,340	3,222	'	'	'	'	0	0	'	0	0	'
Income (Loss) from Continuing Operations Attributable to Parent	63,638	48,314	'	'	-18,472	-18,451	'	-267	-245	'	76,823	61,616	'	'	82,377	67,010	'	5,287	5,149	'	'	'	'	0	0	'	0	0	'
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	136	6,040	'	'	0	0	'	0	0	'	171	6,063	'	'	136	6,040	'	-35	-23	'	'	'	'	0	0	'	0	0	'
Equity of net income (loss) of subsidiaries	0	0	'	'	82,246	72,805	'	0	0	'	0	0	'	'	0	0	'	0	0	'	'	'	'	-82,246	-72,805	'	-82,246	-72,805	'
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest	'	'	'	'	'	'	'	-267	-245	'	'	'	'	'	82,513	73,050	'	'	'	'	'	'	'	-82,246	-72,805	'	'	'	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	63,774	54,354	'	'	63,774	54,354	'	'	'	'	76,994	67,679	'	'	'	'	'	5,252	5,126	'	'	'	'	'	'	'	-82,246	-72,805	'
Comprehensive income (loss)	63,997	54,330	'	'	63,997	54,330	'	-267	-245	'	76,994	67,679	'	'	82,513	73,050	'	5,252	5,126	'	'	-82,246	-72,805	'	'	'	'	'	'
ASSETS	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	346,987	498,508	'	498,508	284,410	437,264	'	0	0	'	49,777	51,869	'	'	62,577	61,244	'	12,800	9,375	'	'	'	'	0	'	'	0	'	'
Accounts Receivable, Net, Current	755,620	'	695,684	'	0	'	0	188	'	210	752,924	'	'	693,729	755,620	'	695,684	336,511	'	'	315,323	'	'	-188	'	-210	-333,815	'	-313,368
Inventory, Net	442,634	'	512,418	'	0	'	0	0	'	0	435,847	'	'	505,567	442,634	'	512,418	6,787	'	'	6,851	'	'	0	'	0	0	'	0
Deferred Tax Assets, Net of Valuation Allowance, Current	126,738	'	135,094	'	0	'	0	0	'	0	126,717	'	'	135,148	126,738	'	135,094	21	'	'	0	'	'	0	'	0	0	'	-54
Other Assets, Current	277,113	'	265,536	'	1,407	'	1,989	0	'	0	250,744	'	'	242,166	275,706	'	263,547	24,962	'	'	21,381	'	'	0	'	0	0	'	0
Assets of Disposal Group, Including Discontinued Operation, Current	46,659	'	49,995	'	0	'	0	0	'	0	46,537	'	'	49,128	46,659	'	49,995	122	'	'	867	'	'	0	'	0	0	'	0
Total current assets	1,995,751	'	2,014,728	'	285,817	'	277,899	188	'	210	1,662,546	'	'	1,693,788	1,709,934	'	1,736,829	381,203	'	'	356,463	'	'	-188	'	-210	-333,815	'	-313,422
Property, Plant and Equipment, Net	317,856	'	305,888	'	0	'	0	17	'	19	313,016	'	'	301,200	317,839	'	305,869	4,840	'	'	4,688	'	'	0	'	0	0	'	0
Goodwill	4,057,456	'	4,057,456	'	0	'	0	0	'	0	4,028,651	'	'	4,028,651	4,057,456	'	4,057,456	28,805	'	'	28,805	'	'	0	'	0	0	'	0
Intangible Assets, Net (Excluding Goodwill)	122,057	'	129,974	'	0	'	0	0	'	0	120,093	'	'	127,798	122,057	'	129,974	1,964	'	'	2,176	'	'	0	'	0	0	'	0
Other Assets, Noncurrent	95,999	'	96,722	'	42,079	'	41,825	19	'	19	53,855	'	'	54,834	53,901	'	54,878	65	'	'	63	'	'	0	'	0	0	'	0
Assets of Disposal Group, Including Discontinued Operation, Noncurrent	85,059	'	87,078	'	0	'	0	0	'	0	85,028	'	'	87,047	85,059	'	87,078	31	'	'	31	'	'	0	'	0	0	'	0
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	0	'	0	'	5,059,898	'	5,131,280	0	'	0	0	'	'	0	0	'	0	0	'	'	0	'	'	-5,059,898	'	-5,131,280	-5,059,898	'	-5,131,280
Total assets	6,674,178	'	6,691,846	'	5,387,794	'	5,451,004	224	'	248	6,263,189	'	'	6,293,318	6,346,246	'	6,372,084	416,908	'	'	392,226	'	'	-5,060,086	'	-5,131,490	-5,393,713	'	-5,444,702
Current liabilities of continuing operations	584,392	'	587,107	'	37,402	'	83,028	0	'	0	852,060	'	'	793,461	547,178	'	504,289	28,745	'	'	23,986	'	'	-188	'	-210	-333,815	'	-313,368
Debt, Current	528,475	'	527,204	'	528,475	'	527,204	0	'	0	0	'	'	0	0	'	0	0	'	'	0	'	'	0	'	0	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Current	17,407	'	18,846	'	0	'	0	0	'	0	17,404	'	'	18,829	17,407	'	18,846	3	'	'	17	'	'	0	'	0	0	'	0
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent	840	'	1,398	'	'	'	'	'	'	'	840	'	'	1,398	840	'	1,398	0	'	'	0	'	'	'	'	'	'	'	'
Temporary Equity, Liquidation Preference	329,425	'	331,101	'	329,425	'	331,101	0	'	0	0	'	'	0	0	'	0	0	'	'	0	'	'	0	'	0	0	'	0
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Long-term Debt, Excluding Current Maturities	1,417,491	'	1,418,819	'	1,405,876	'	1,405,628	0	'	0	11,615	'	'	13,191	11,615	'	13,191	0	'	'	0	'	'	0	'	0	0	'	0
Deferred income tax liabilities	1,023,415	'	1,012,733	'	368,532	'	363,240	0	'	0	640,955	'	'	635,640	654,883	'	649,493	13,928	'	'	13,907	'	'	0	'	0	0	'	-54
Other noncurrent liabilities	54,649	'	53,835	'	0	'	0	0	'	0	52,960	'	'	52,072	54,649	'	53,835	1,689	'	'	1,763	'	'	0	'	0	0	'	0
Stockholders' equity	2,718,084	'	2,740,803	'	2,718,084	'	2,740,803	224	'	248	4,687,355	'	'	4,778,727	5,059,674	'	5,131,032	372,543	'	'	352,553	'	'	-5,059,898	'	-5,131,280	-5,059,898	'	-5,131,280
Total liabilities and stockholders' equity	6,674,178	'	6,691,846	'	5,387,794	'	5,451,004	224	'	248	6,263,189	'	'	6,293,318	6,346,246	'	6,372,084	416,908	'	'	392,226	'	'	-5,060,086	'	-5,131,490	-5,393,713	'	-5,444,702
Cash flows from operating activities:	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net cash flows (used in) from operating activities	177,498	108,895	'	'	-1,854	-3,365	'	0	0	'	178,130	114,407	'	'	179,352	112,260	'	1,222	-2,147	'	'	'	'	'	'	'	'	'	'
Cash flows from investing activities:	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Proceeds from Divestiture of Businesses, Net of Cash Divested	'	'	'	'	0	'	'	0	'	'	3,629	'	'	'	3,629	'	'	0	'	'	'	'	'	'	'	'	'	'	'
Capital expenditures	-26,165	-22,415	'	'	0	0	'	0	0	'	-25,702	-22,099	'	'	-26,165	-22,415	'	-463	-316	'	'	'	'	'	'	'	'	'	'
Other Investing Activities	-284	140	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Payments for (Proceeds from) Other Investing Activities	12	854	'	'	0	-227	'	0	0	'	-284	367	'	'	-284	367	'	0	0	'	'	'	'	'	'	'	'	'	'
Net cash flows used in investing activities	-22,820	-22,275	'	'	0	-227	'	0	0	'	-22,357	-21,732	'	'	-22,820	-22,048	'	-463	-316	'	'	'	'	'	'	'	'	'	'
Cash flows from financing activities:	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Payments on Term Loans	-5,313	-5,313	'	'	-5,313	-5,313	'	0	0	'	0	0	'	'	0	0	'	0	0	'	'	'	'	'	'	'	'	'	'
Payments on long-term borrowings and obligations	-39,030	-1,684	'	'	-39,030	-1,684	'	0	0	'	0	'	'	'	0	0	'	0	'	'	'	'	'	'	'	'	'	'	'
Proceeds from (Repayments of) Bank Overdrafts	-3,537	-9,774	'	'	-2,611	-10,900	'	0	0	'	-926	'	1,126	'	-926	1,126	'	0	'	0	'	'	'	'	'	'	'	'	'
Payments for Omnicare common stock repurchase	-95,417	-302	'	'	-95,417	-302	'	0	0	'	0	0	'	'	0	0	'	0	0	'	'	'	'	'	'	'	'	'	'
Dividends paid	-19,596	-14,479	'	'	-19,596	-14,479	'	0	0	'	0	0	'	'	0	0	'	0	0	'	'	'	'	'	'	'	'	'	'
Proceeds from (payments for) Other Financing Activities including disc Ops	4,817	537	'	'	172,321	89,860	'	0	0	'	-167,504	-89,323	'	'	-167,504	-89,323	'	0	0	'	'	'	'	'	'	'	'	'	'
Net Cash Provided by (Used in) Financing Activities	-158,076	-31,015	'	'	10,354	57,182	'	0	0	'	-168,430	-88,197	'	'	-168,430	-88,197	'	0	0	'	'	'	'	'	'	'	'	'	'
Net increase (decrease) in cash and cash equivalents	-3,398	55,605	'	'	8,500	53,590	'	0	0	'	-12,657	4,478	'	'	-11,898	2,015	'	759	-2,463	'	'	'	'	'	'	'	'	'	'
Cash and cash equivalents at beginning of period	356,001	444,620	'	498,508	275,910	383,674	'	0	0	'	68,050	49,108	'	'	80,091	60,946	'	12,041	11,838	'	'	'	'	0	'	'	0	'	'
Cash and cash equivalents at end of period	346,987	498,508	'	498,508	284,410	437,264	'	0	0	'	49,777	51,869	'	'	62,577	61,244	'	12,800	9,375	'	'	'	'	0	'	'	0	'	'
Net Cash Provided by (Used in) Discontinued Operations	5,616	1,717	'	'	0	0	'	0	0	'	5,616	1,717	'	'	5,616	1,717	'	0	0	'	'	'	'	'	'	'	'	'	'
Cash and Cash Equivalents Period Increase (Decrease) from Continuing Operations	($9,014)	$53,888	'	'	$8,500	$53,590	'	$0	$0	'	($18,273)	$2,761	'	'	($17,514)	$298	'	$759	($2,463)	'	'	'	'	'	'	'	'	'	'